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SUMMARY 
Recently, combination treatment of photodynamic therapy (PDT) with dendritic 
cell (DC)-based immunotherapy also termed photoimmunotherapy has been shown to be 
an effective anti-tumor treatment. In these studies, the DCs were expanded in vitro and 
primed in vivo via intratumoral injection of DCs. In the present study, the anti-tumor 
effectiveness of a novel anti-cancer treatment via photoimmunotherapy uitilizing the 
combination of hypericin (HY)-PDT and in vivo stimulation of DCs via pNGVL3-hFlex 
plasmid DNA was investigated in murine B16 melanoma.  The anti-tumor effectiveness 
of PDT alone, photoimmunotherapy and control were compared in vivo in various murine 
models including a primary tumor model, distant established tumor (metastatic) model 
and when exposed to a second tumor challenge (tumor vaccine model). 
Photoimmunotherapy was superior to both control and PDT alone in suppressing tumor 
growth on a small established contralateral tumor and when exposed to a second tumor 
challenge. However, it was not effective in suppressing the growth of a large established 
contralateral tumor. Photoimmunotherapy was also not superior to PDT alone in 
controlling the primary tumor.  
In conclusion, photoimmunotherapy using HY-based PDT and in vivo DC 
expansion by pNGVL3-Flex plasmid DNA is a novel anti-cancer modality which results 
in an effective systemic tumor specific anti-tumor immune response which suppresses 
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1.1 Photodynamic Therapy (PDT) 
Photodynamic therapy (PDT) is a clinically established physicochemical modality for the 
local treatment of cancer (Korbelik and Sun, 2006). It is also presently utilized for the 
treatment of various non-malignant diseases (Dougherty et al., 1998). Although light has 
been used for the treatment of various diseases for over thousands of years, the 
development of PDT as a therapeutic modality for human diseases has occurred only over 
100 years ago (Daniell and Hill, 1991; Ackroyd et al., 2001; Moan and Peng, 2003). At 
present, PDT has been advocated as a promising therapeutic modality for many human 
cancers, and clinical trials testing its use are being performed for malignancies afflicting 
almost any organ in the human body. Some of these include cancers involving the head 
and neck region, brain, breast, lung, skin, liver, bile ducts, bladder and gastrointestinal 
tract (Dougherty, 2002, Dolmans 2003). Currently, PDT is approved for use as curative 
treatment for early-stage cancers and for palliation in advanced malignancies. 
 
1.1.1 PDT-induced cell death    
 PDT induces both apoptotic and necrotic cell death. The balance between 
apoptosis and necrosis after PDT in vitro depends on several factors including 
photosensitizer concentration, light fluence rate, oxygen concentration and type of tumor 
(Castano et al., 2005). Numerous in vivo and in vitro studies have been reported 
examining the pathways of apoptosis induced after PDT. These studies have described 
various signaling pathways, mitochondrial events and apoptotic mediators (Castano et al., 
2006; Agostinis et al., 2004; Moor, 2000). The mechanism of PDT’s tumoricidal effects 
is a complex interplay of various biochemical processes in vivo. The 3 key components 
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considered essential for effective PDT are the presence of the photosensitizer, light and 
oxygen. Briefly, PDT involves the systemic administration of a photosensitizer that 
demonstrates preferential accumulation in tumor cells, followed by illumination of the 
tumor with a laser beam. This generates a complex photochemical reaction which 
produces cytotoxic intermediates such as reactive oxygen species (ROS) that can destroy 
the tumor cells (Dougherty et al., 1998). Tumor destruction results not only from these 
direct cytotoxic effects but also from the induction of a local inflammatory response 
(Dougherty et al., 1998). The preferential accumulation of the photosensitizer in tumors 
is a critical step in PDT. This process allows targeting of tumor tissue and reduces 
damage to normal tissue (collateral damage). Although the mechanism of photosensitizer 
retention in tumor compared to normal tissue has not been fully elucidated, a multitude of 
factors have been proposed which contribute to this preferential distribution of 
photosensitizers to tumor tissue. Changes in properties of the tumor tissues itself such as 
decrease in pH, elevation of low density protein receptors, and presence of macrophages 
may contribute to this preferential distribution. Other factors such as presence of a large 
interstitial space, leaky vasculature, compromised lymphatic drainage, and high lipid 
content have also been postulated to favor preferential distribution of photosensitizers to 
tumor tissues (Dougherty et al., 1998). 
 Presently, it is believed that several biochemical processes contribute to the anti-
tumor effects of PDT. Some of these key processes include: 1) direct tumor cell killing 
induced by photooxidative damage, (Penning and Dubbelman, 1994) 2) vascular damage 
and occlusion causing tumor cell damage via deprivation of oxygen and nutrients (Fingar, 
1996) and 3) immune-mediated anti-tumor effects (de Vree et al., 1996; Korbelik et al., 
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1996; Korbelik et al., 1997). The relative contribution of each of these mechanisms of 
tumor destruction is difficult to determine but it is highly likely that all of these are 
necessary for successful outcome after treatment (Jalili et al, 2004). 
Direct tumor cell damage by oxygen free radicals is the main mechanism of tumor 
cell killing via PDT. When the photosensitizer absorbs light, it is activated to an excited 
singlet state. The activated photosensitizer is then rapidly converted to the longer-lived 
triplet state due to intersystem crossing (Ryter and Tyrell, 1998). Eventually, the latter 
can undergo two types of reactions. In type I mechanisms, a photosensitizer radical is 
produced which in the presence of oxygen can generate superoxide radical anions, 
peroxides and hydroxyl radicals (Ali and Olivo, 2003). Alternatively, in type II 
mechanisms, singlet oxygen is produced by reaction of the triplet state of the 
photosensitizer with oxygen.  
Studies have demonstrated that vascular damage occurs after PDT which leads to 
severe and persistent post-PDT tumor hypoxia and nutrient depletion which may 
contribute to long-term tumor control. PDT has been shown to cause vessel constriction, 
vessel leakage, thrombus formation and leukocyte adhesion leading to platelet activation 
and thromboxane release which results in vessel damage and blood flow stasis (Fingar et 
al., 1993; Fingar, 1996). Inhibition of nitric oxide production and release by PDT also 
results in vasoconstriction (Gilissen et al., 1993). These PDT-induced changes in the 
tumor results in microvascular damage and collapse leading to tumor cell destruction.  
 
1.1.2 PDT-induced immune response 
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Besides the direct anti-tumor effects via ROS and ischemic tumor death via 
vascular damage, there is accumulating evidence that PDT results in a strong anti-tumor 
immune response. The anti-tumor immune response after PDT is composed of both the 
non-tumor specific response secondary to the acute inflammatory reaction and tumor-
specific immune reaction. After PDT, a wide range of photooxidative lesions produced in 
the cytoplasm and membrane of tumor cells, tumor vasculature and surrounding stromal 
elements results in the rapidly induced massive damage that threatens local homeostasis 
(Korbelik and Sun, 2006). These result in a strong host response which aims to contain 
the altered homeostasis, remove dead tissue and promote tissue healing of the affected 
region (Korbelik and Cecic, 2003). This host reaction to PDT manifests as the 
inflammatory reaction, immune response and acute phase response (Dougherty et al., 
1998). Various inflammatory  mediators are released and expressed at the PDT treatment 
site including heat shock proteins (HSP), cytokines, archidonic acid metabolites and 
proteins from the complement system (Cecic and Korbelik, 2002; Gollnick et al., 2003; 
Korbelik et al. 2005).  Key components of the innate immune system such as Toll-like 
receptors (TLR) and the complement system are activated and play a critical role in PDT-
mediated tumor destruction. Practically every component of the innate immune system 
participate in tumor destruction including neutrophils, mast cells, macrophages, natural 
killer cells and elements of the complement system such as opsonins and membrane 
attack complex (Korbelik and Sun, 2006; Dougherty et al., 1998). Subsequently, the 
activation of the innate immune system culminates in the development of the acquired 
tumor specific immune response (Dougherty et al, 1998). Innate immune cell presence 
and activation is essential for the development of acquired immunity and innate cell 
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infiltration into the treated tumor bed is a hallmark of PDT (Kousis et al., 2007; 
Dougherty et al., 1998). The acute inflammation caused by PDT-induced tumor cell 
necrosis attracts leucocytes to the tumor and increases antigen presentation. Heat shock 
protein (HSP) 70 which is thought to be one of the most important cellular factors 
involved in PDT-induced immune response is released and is involved in various 
interactions with antigen presenting cells (APCs) including dendritic cells (DCs). 
Tumor-specific immune response has been shown to be an important mechanism 
in PDT-induced tumor destruction. There are numerous preclinical studies that suggest 
that PDT enhances the systemic anti-tumor immune response although the mechanism 
behind this enhancement remains unclear (Castano et al., 2006). Dougherty et al pointed 
out that the tumor specific immune response may not be important in initial tumor cell 
damage but its effect may be essential in maintaining long-term tumor control 
(Dougherty et al., 1998). APCs such as DCs, macrophages and B lymphocytes are 
important mediators in the initial step of tumor-specific immune response. Cancer cells 
damaged or destroyed by PDT are processed by APCs and the antigens are presented on 
the cell membranes via major histocompatibility (MHC) class molecules. These tumor 
antigens are recognized by T helper lymphocytes which are than activated and 
subsequently sensitize cytotoxic T lymphocytes to the tumor antigens. The activation, 
expansion and differentiation of T lymphocytes lead to the development of tumor-
specific immunity. These tumor sensitized lymphocytes have the potential to eliminate 
disseminated tumor cells. Thus, PDT may be associated with a systemic immune reaction 
and anti-tumor effect although PDT by itself is by definition a local therapeutic modality. 
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The findings of several studies that lymphoid cells are essential for preventing the 
recurrence of PDT-treated tumors provide further support for the role of the tumor-
specific anti-tumor immune reaction in PDT. Korbelik et al documented that PDT-
mediated curability of mouse cancers was reduced or non-existent in severe combined 
immune deficient mice (Korbelik and Dougherty, 1999; Korbelik et al., 1999). This could 
be restored after bone marrow transplant or T-cell transfer from immunocompetent mice. 
Furthermore, immune memory cells could be recovered from distant lymphoid sites 
suggesting that long-lasting systemic immunity was raised against even poorly 
immunogenic tumors (Korbelik and Dougherty, 1999; Korbelik et al., 1999). Hendrzak-
Henion et al., 1999 also demonstrated that after PDT treatment, immune-deficient mice 
could not demonstrate complete tumor remission as opposed to immune-competent mice 
which were permanently cured.  The results of these studies suggest that PDT can 
generate immune memory cells and thus has the potential to be combined with 
immunotherapy protocols in the treatment of malignant tumors. This potential has since 
been confirmed by several studies which have demonstrated that immune-stimulating 
cytokines, immunomodulators and adoptive transfer of immune cells have the ability to 
enhance the anti-tumor effectiveness of PDT (Golab et al., 2000; Krosl et al., 1996; 
Korbelik et al., 2001). Further evidence of the anti-tumor immune effects of PDT were 
the observations in some studies that localized therapy with PDT was capable of 
controlling distant disease (Gomer et al., 1987).  In the recent study by Kabingu et al., 
2007, the investigators found that PDT-treatment of subcutaneous tumors resulted in 
inhibition of the growth of distant lung metastases. This study was the first to 
demonstrate that CD8+ T cell was responsible for the control of tumors growing outside 
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the treatment field following PDT. Earlier studies showing inhibition of distant tumor 
growth away from the treatment field did not attempt to determine the specific effector 
cell-type responsible for tumor control (Gomer et al., 1987; Blank et al, 2001). CD8+ T 
lymphocyte mediated control of the distant lung tumors was found to be independent of 
CD4+ T lymphocytes but dependent on natural killer (NK) cells (Kabingu et al., 2007). 
These results were consistent with the earlier findings of Korbelik and Dougherty, 1999 
whereby depletion of CD8+ T cells substantially impaired the ability of PDT to suppress 
the long-term growth of EMT6 as opposed to the depletion of CD4+ T cells.  Anecdotal 
clinical cases of regression of distant tumors after local PDT have also been reported in 
the literature (Thong et al., 2007; Naylor et al., 2006). Thong et al. reported an interesting 
case of a histologically-proven multifocal cutaneous angiosarcoma of the head and neck 
region. The patient underwent localized Fotolon-PDT of several selected lesions (Thong 
et al., 2007). Spontaneous regression was subsequently observed in several of the 
cutaneous lesions at distant sites.  Biopsies demonstrated that these distant lesions were 
infiltrated by CD8+ T-cell clones which suggest that PDT resulted in a systemic acquired 
immune response which resulted in the systemic anti-tumor activity. 
 
1.1.3 PDT-generated anti-tumor vaccines 
In 2002, Gollnick et al., 2002 performed the first study to directly demonstrate the ability 
of PDT to enhance tumor immunogenicity and to generate an effective anti-tumor 
vaccine.  They demonstrated that PDT-generated cell lysates were immunogenic and 
PDT-generated vaccines were more effective than ultraviolet (UV) or ionizing radiation-
generated vaccines. These vaccines were tumor-specific, induced a cytotoxic T-cell 
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response and did not require the co-administration of an adjuvant to be effective. PDT-
generated lysates were shown to activate DCs to express interleukin (IL)-12 which is 
critical in inducing a cytotoxic T-cell response. This capacity of PDT to stimulate both 
phenotypic and functional maturation of DCs was postulated to be the key reason behind 
the effectiveness of PDT in generating an effective anti-tumor vaccine. Subsequently, 
their findings were confirmed more recently by Korbelik and Sun, 2006. In a similar 
study, Korbelik and Sun, 2006 demonstrated that PDT-generated vaccines were 
significantly superior to vaccines generated by lysed cells or X-ray treated cells in 
producing tumor growth retardation, tumor regression and even complete tumor cures. 
This study further confirmed the unique advantage of PDT for the generation of anti-
tumor vaccines. Moreover, the PDT-generated vaccines were tumor-specific as 
documented by its lack of efficacy against mismatched tumors. This finding was a firm 
indication that the observed anti-tumor effects were due to a PDT-induced tumor-specific 
immune response. It also further demonstrated that vital components of the tumor-
specific immune response such as DCs, memory T- and memory B-cells were 
dramatically increased at the tumor site and its draining nodes. Korbelik and Sun, 2006 
also demonstrated that vaccine cells retrieved from the treatment site 1 hour after 
injection were intermixed with DCs, expressed HSP70 on their surface and were 
opsonized by complement C3 verifying the findings of several earlier studies (Castano et 
al., 2006). More recently, Kousis et al., 2007 demonstrated that the induction of the anti-
tumor immune response after PDT is dependent on neutrophil infiltration into the treated 
tumor bed. They further suggested that neutrophils may be responsible for directly 
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stimulating T-cell proliferation and/or survival. However, these did not seem to affect DC 
maturation or T-cell migration. 
Unlike PDT, most of the routinely used anti-cancer therapies cause 
immunosuppression. Radiotherapy and chemotherapy delivered at doses sufficient to 
produce tumor destruction are well-known to be toxic to the bone marrow which results 
in myelosuppression and hence, immunosuppression (Castano, et al., 2006). Nonetheless, 
it is important to note that low doses of radiotherapy and chemotherapy may enhance the 
immune system including induction of HSPs (Sierra-Rivera et al., 1993). Major surgery 
has also been reported to produce immunosuppression, leading to diminished lymphocyte 
and natural (NK) cell function (Ng et al., 2005). Hence, unlike these traditionally 
available therapeutic modalities, PDT has the properties of an ideal cancer therapy which 
not only results in primary tumor destruction but also triggers the immune system to 
recognize and destroy remaining tumor cells which may be local or distant (Castano et 
al., 2006).  
 
1.2 Hypericin (HY)-mediated PDT. 
The ideal photosensitizer for PDT should have the following properties including: 
chemical purity, minimal dark toxicity, significant light absorption at wavelengths that 
penetrate tissue deeply, high tumor selectivity and rapid clearance from normal tissue 
(Ali and Olivo, 2003; Pass, 1993; Fisher et al., 1995). Various photosensitizers have been 
approved and are currently used for the clinical treatment of cancer. These include 
Metvix (5-aminiolevulinic acid- methylesther), Foscan (meta-tetrahydroxyphenylchlorin) 
and Photofrin (Hematoporphyrin derivative). The most commonly used photosensitizer 
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presently is probably Photofrin. However, this first generation photosenstizer has several 
notable limitations including the low light absorption, low tumor tissue selectivity and 
long duration of cutaneous photosensitivity (Dolmans et al., 2003). This has led 
researchers  search for newer improved drugs with properties closer to that of an ideal 
photosensitizer.  
HY is a chemical found in the Hypericum species of herb of which hypericum 
perforatum or St John’s Wort is the most common genum. It is a herb with golden yellow 
flowers (Lavie et al, 1995). The proto-forms of HY and its congener pseudo-hypericin 
exist as dark-coloured granules in minute glands of St John’s Wort (Southwell and 
Bourke, 2001). These structures of partially cyclic precursors are transformed into 
naphthodianthrone analogues; HY and pseudoHY on light irradiation. The chemical 




Figure 1. Chemical structure of HY 
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 Under physiological conditions, HY is present as a monobasic salt. It can be taken 
up by cellular lipid membrane structures and behave as lipophilic ion pairs (Lavie, et al, 
1995). HY exhibits bright fluorescence detection in organic solvent, which makes it an 
ideal diagnostic tool for fluorescence detection (Olivo et al, 2003). The utility of intra-
vesical instillation of HY for the detection of flat bladder neoplasms have been 
demonstrated in a clinical trial (D’Hallewin et al, 2002). HY is a powerful photosensitizer 
as it demonstrates a high yield of singlet oxygen and its minimal dark toxicity makes it a 
very promising and useful clinical tool (Agostinis, 2002). It is metabolized rapidly in vivo 
and has minimal toxic properties when administered sytemically (Meruelo et al., 1988). 
In vivo studies have demonstrated that HY binds well to tumor cells and are retained for 
longer periods than normal tissues (Chung et al., 1984). HY has been studied in several 
clinical trials for the treatment of skin cancers, brain tumors and cutaneous lymphoma 
(Alecu et al., 1998, Lavie et al., 2000). However, its use has never been evaluated in 
malignant melanoma. 
 HY has an extremely broad absorption spectra making it readily excitable by a 
variety of light sources (Miller et al., 1995; Schempp et al., 1999) It is maximally 
activated at a wavelength of light of approximately 470 nm (Ali and Olivo, 2003). The 
photodynamic effects of HY have been well-investigated by numerous investigators. It 
has been shown that high PDT doses induce rapid cell necrosis whereas lower 
intermediate doses induce apoptosis (Agostinis et al., 2002, Ali et al., 2001). The 
apoptotic pathway of cell death after HY-PDT has been well-elucidated. This has been 
shown to be mediated by the mitochondria followed by activation of the caspase cascade 
(Ali et al., 2001) possibly via hydrogen peroxide production (Ali et al., 2002). Assefa et 
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al. demonstrated that activation of c-Jun N-terminal kinase (also known as stress 
activated protein kinase) and p38 mitogen-activated protein kinase increases the 
resistance to HY-induced apoptosis (Assefa et al., 1999; Hendrickx et al., 2003). Other 
effects of HY-PDT reported include activation of lipid peroxidation (Chaloupka et al., 
1999; Miccoli et al., 1998), inhibition of protein kinase C, inhibition of growth factor 
stimulated protein kinase (Agostinis et al., 1995; de Witte et al., 1993) and increase in 
matrix metalloproteinase-1 (Du, et al., 2004). In NPC/HK1 nasopharyngeal carcinoma 
cells, it has been shown that HY-PDT produced maximal tumor regression in mice when 
the incubation period was 1 hour and 6 hours after instillation of HY whereas HY-PDT 
was less effective when incubation periods were between this time interval (Du et al., 
2003). Du et al., 2003 further demonstrated that at an incubation of 1 hour the HY 
concentration was maximal in the mouse plasma whereas at an incubation of 6 hours, HY 
concentration was maximal in the tumor tissue and low in plasma. Hence it was 
postulated that HY-PDT could induce tumor necrosis and shrinkage via 2 mechanisms ie. 
via vascular damage and direct tumor cell killing. 
It is essential to note that different cell types may demonstrate a different response 
to HY-PDT (Kyriakis, 1999; Lavie et al., 1999). It is well-known that the mechanism of 
tumor destruction by HY-PDT hinges on several important factors including type of 
tumor cell, tumor microvasculature, host inflammatory response and host immune 
response (Dougherty et al., 1998). 
  
1.3 Immunotherapy with DCs 
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Protective immunity results from the combined action of the innate and adaptive 
immune system (O’Neill and Bhardwaj, 2007). The innate arm of the immune system is 
composed of phagocytic cells, NK cells and complement which provide an early and 
rapid non-specific immune response. Both B and T cells make up the adaptive immune 
system which is critical for the generation of immunologic memory. Proper functioning 
of both the innate and adaptive immunity is critical against the development of malignant 
tumors (Smyth et al, 2006). APCs provide an important link between the two arms of the 
immune system. They process intra- and extra-cellular proteins into antigenic peptides 
which are then presented to cells of the adaptive immune system. Although, B cells, 
macrophages, monocytes and DCs can all function as APCs, DCs are thought to be the 
most potent APC of them all (Banchereau, et al, 2000). This has been demonstrated by 
both in vitro and in vivo experiments (Steinman and Pope, 2002). 
As with other APCs, DCs play an important role in activating both the innate and 
adaptive components of the immune system via interaction with naïve T-cells (Steinman, 
1997). DCs drive both the cell-mediated and humoral arms of the adaptive immune 
response. They express high levels of major histocompatibility (MHC) molecules and 
immune co-stimulatory accessory molecules and are responsible for the secretion of 
many potent T-cell-activating cytokines which are critical for an effective immune 
response (Fong and Hui, 2002). DCs specialize in acquiring, processing and presenting 
antigens to naive, resting T-cells activating them to induce an antigen-specific immune 
response (Banchereau et al., 1998). The process of efficiently capturing antigens is 
restricted to the immature stage of development when DCs express low levels of MHC 
and co-stimulatory molecules. During this immature stage, DCs are inefficient APCs. 
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Additional signals frequently referred to as danger signals are essential for inducing the 
maturation of DCs and to transform them into effective APCs. Although this danger 
signals necessary for the activation of DCs has not been unequivocally resolved, there is 
mounting evidence that some of the HSPs play a critical part (Flohe et al., 2003, Chen et 
al., 1999). DCs are capable of processing both endogenous (synthesized within the DC 
cytosol) and exogenous (from the extra-cellular environment) antigens (Aloysius et al., 
2006). Examples of exogenous antigens include viruses, bacteria, cell products from 
necrotic or apoptotic cells, immune complexes and HSPs. These antigens are captured 
through various receptors via various mechamisms like endocytosis, pinocytosis or 
phagocytosis. These captured antigens are processed into immunogenic fragments which 
bind to MHC class I and II molecules which are transported to the cell surface for 
recognition by and activation of antigen-specific T-cells. Endogenous antigens on the 
other hand are broken down in the cytosol. These are then transported into the 
endoplasmic reticulum via special transporters (transporters of antigen presentation). The 
peptides are loaded to MHC class I molecules within the endoplasmic reticulum and are 
transferred to the cell surface via the golgi-body network for presentation to CD8+ T 
cells. 
DCs are derived from bone marrow progenitors and circulate in the blood as 
immature precursors. They migrate to various tissues such as the subepithelial 
compartment of the respiratory tract, basal layer of the epidermis, in the lamina propria of 
gut wall and in organized lymph follicles such as Peyer’s patches (Aloysius et al., 2006). 
Here, they constantly sample the micro-environment for foreign antigens. These are then 
captured, processed and than presented on the cell surface linked to MHC molecules. 
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After stimulation, DCs undergo further maturation and subsequently migrate to 
secondary lymphoid tissues where they present antigens to T-cells and induce an antigen 
specific immune response (Austyn et al., 1988). When matured, DCs lose their ability to 
take up antigen. The homing of DCs into nearby regional lymph nodes has been shown to 
be dependent on the expression of chemokine receptor 7.  DCs are also responsible for 
inducing the humoral arm of the acquired immune system (Aloysius et al., 2006). They 
induce memory B cell differentiation into effector plasma cells and regulate B cell 
priming. More recent evidence also suggests that DCs play a crucial role in regulating the 
hosts innate immunity (Degli-Espost and Smyth, 2005). The complex interaction and 
cross-talk between DCs and NK cells play a vital role in this process.   
 Cell surface phenotyping has shown that are as many as 5 distinct subtypes of 
DCs at least in mice (O’Neill and Bhardwaj, 2007; Shortman and Liu, 2002; Clark et al., 
2005). In humans, the three best characterized DCs include cells resembling epidermal 
Langerhans cells, cells resembling dermal or interstitial DCs and plasmacytoid DCs 
(O’Neill and Bhardwaj, 2007). The precise origin of the different DC subtypes is unclear 
although it has previously been thought that most DCs are of myeloid origin. In mice, it 
has been shown that DC can be derived from common myeloid and common lymphoid 
progenitors as well as a third progenitor cell without either myeloid or lymphoid potential 
(del Hoyo et al., 2002)    
 There is presently vast amount of data in the literature which support the concept 
that cancer patients can spontaneously develop specific adaptive immune responses to 
tumor associated antigens (TAAs) (Aloysius et al., 2006). Various tumor antigens have 
been discovered in different malignancies which are potential immunological targets for 
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T-cells. Effective T-cell response to these antigens forms the basis for immune 
elimination of tumor cells. DCs are professional APCs which are responsible for 
presenting TAAs to immature T-cells in regional tumor draining lymph nodes leading to 
the expression of tumor specific CD8+ T-cells. However, there is evidence to suggest that 
there is a decrease in the absolute numbers of peripheral circulating DCs and tumor 
infiltrating DCs in various malignancies. Moreover, there also appears to be abnormal 
differentiation and maturation of DCs in cancer patients. As a consequence of this 
impaired tumor recognition and antigen presentation mechanisms by DCs, immune 
evasion occurs and the tumor progresses (Aloysius et al., 2006). These findings have 
prompted some investigators to utilize regimes involving ex vivo differentiation and 
maturation of DCs in an optimal milieu before using them for anti-cancer DC 
immunotherapy. 
 Cancer immunotherapy has a very long history (although unrecognized) (Du, 
2004). It was noted by the Egyptians that surgical opening of the tumor site could induce 
tumor regression, presumably through the generation of infection and activation of the 
immune system (Hoption Cann et al., 2003; Castano et al., 2006). More then a hundred 
years ago, William Coley who was a surgeon found that certain infections could induce 
tumor regression and he created a ‘vaccine’ based initially on bacteria (Castano et al., 
2006). The legacy of his findings continues until today. For example, the bacillus 
Calmette-Guerin (BCG) vaccine derived from Mycobacterium bovis which is used for 
the prevention of tuberculosis is still presently utilized for the treatment of superficial 
bladder cancer (Bassi, 2002). Since these initial studies, groundbreaking discoveries in 
immunology have identified the key roles of various mediators in propogating the anti-
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tumor immune response and numerous immunotherapy modalities using ILs, DCs and 
lymphocytes have been generated.  
  DCs have generated great interest as a vaccine adjuvant because of their potent 
immuno-stimulatory capacity and ability to prime immature T-cells (Banchereau and 
Palucka, 2005). As DCs are present in most tissues especially tumors at a very low 
frequency (which is therefore the most likely rate-limiting step), the addition of 
autologous DCs should theoretically result in a stronger and more durable tumor-specific 
immunity (Saji et al., 2006). DC-based immunotherapy can be broadly classified into in 
vivo mobilization and in vitro manipulation techniques. Presently, the most common 
approach for DC immunotherapy is to isolate large numbers of DCs by culturing bone 
marrow progenitors ex vivo in the presence of cytokines, loading the DCs with antigens 
and reinjecting them back to the host (O’Neill and Bhardwaj, 2007). This approach has 
been extremely successful in murine models whereby numerous studies have 
demonstrated that these DC-based vaccines can protect mice against a second tumor 
challenge and can even cure mice harboring established tumors (Celluzzi et al., 1998; 
Gilboa et al., 2007). In humans, DC-based immunotherapy have also demonstrated 
promising results although these have not been as dramatic as those seen in mice. Clinical 
and immune responses have been reported for various malignancies in patients including 
B cell lymphoma, metastatic melanoma and metastatic renal cell carcinoma (Banchereau 
et al., 2001; Tuenttenberg et al., 2006; Wierecky et al., 2006). A significant and notable 
drawback of ex vivo DC-based vaccines is that the ex vivo production of individually 
tailored cellular therapies is laborious and costly. Hence, the use of in situ approaches 
which take advantage of the biological properties of DCs in vivo has generated a  
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tremendous amount of interest. Approaches that can mobilize DCs to accessible sites 
where they can be matured and primed with antigens in vivo are being developed in the 
hope that this may lead to effective therapies without the need for expensive and 
laborious processes (Steinman and Pope, 2002). Some of these approaches include 
systemic mobilization of DCs using Flt3 ligand, local injection of chemokines such as 
macrophage inflammatory protein (MIP)-3β, use of DNA vaccines containing bacterial 
CpG motifs and the use of topical compounds such as Imiquimod (a TLR 7 agonist) 
(O’Neill and Bhardwaj, 2007; Homey et al., 2002) 
Administration of DCs loaded ex vivo with tumor antigens have been shown to 
elicit both potent anti-tumor and anti-viral immune response in vitro and in vivo (Pagilla 
et al., 1996, Celluzzi et al., 1996). DCs, regardless of the route of administration has been 
shown to induce antigen specific T-cell immunity in cancer patients (Fong et al., 2001). 
DCs pulsed with tumor derived peptides, genes or lysates, as well as DCs fused with 
tumor cells, have all been shown to be effective as therapeutic cancer vaccines (Saji et al., 
2006). DC-based vaccination has demonstrated promising results in clinical trials 
involving patients with various advanced malignancies. These are well-tolerated and are 
capable of inducing specific anti-tumor T-cell responses resulting in tumor regression. 
However, on the whole the therapeutic efficacy of DC-based vaccination has been limited 
and various investigators have suggested combination therapy with other therapeutic 
modalities to enhance its potency. Anti-tumor treatment modalities such as systemic anti-
tumor drugs, radiation and radiofrequency ablation have all been combined effectively 
with DC immunotherapy (Saji et al., 2006). PDT is another modality which has been 
shown to demonstrate great potential when used in combination with immunotherapy. 
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This combination modality which is still under investigation is termed 
photoimmunotherapy (Jalili et al., 2004). This modality of treatment is the main focus of 
the present study and will be discussed in detail later.  
Intra-tumoral injection of DCs offers the theoretical advantage of in vivo loading 
and activation of DCs which should be superior to in vitro loading of DCs with tumor 
antigens. The inflammatory milieu in vivo with its abundance of cytokines, various 
immune mediators and cells allows a broad and complex range of immune interactions 
which may result in an effective anti-tumor immune response. However, this technique is 
still associated with the problems associated with the culturing of DCs from bone marrow 
(BM) progenitors in vitro. This in vitro technique is associated with many practical 
problems including the required usage of many expensive cytokines in the growth 
medium, contamination of cultures and inducing possible changes in the physiological 
properties of DCs (Fong and Hui, 2002). Hence, some investigators have proposed that 
the expansion of DCs in vivo may be advantageous as the generation of potentially 
multiple DC subsets might be of great importance in eliciting optimal antigen-specific 
responses (Liu et al., 2001). Recently, the administration of the novel human 
hematopoietic growth factor, FLT-3 ligand (hFlt-3L) had been shown to have a profound 
effect on the generation of functional mature DCs in various organs (Maraskovsky et al., 
1996). Subsequently, several studies have also shown that Flt-3L also results in 
recruitment of DCs to the tumor site (Lynch et al., 1997; Esche et al., 1998). Presently, 
despite the immense potential of DC-based anti-tumor vaccines being frequently 
demonstrated in pre-clinical studies; the clinical efficacy of DC-based vaccines remains 
limited (Saji et al., 2006; Fong and Hui., 2002). One of the many possible reasons 
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proposed for its limited clinical applicability and the variable results obtained in inducing 
strong anti-tumor immunity, particularly cytotoxic T-cell responses is that DCs are 
activated in vitro by antigen loading (Saji et al., 2006). The main problem with in vitro 
activation is that DCs are loaded with only 1 or a few tumor antigens whereas in vivo 
tumors potentially contain a few thousand antigens (Saji et al., 2006). Hence, in vivo 
activation of DCs may overcome this limitation and several studies combining DC- based 
vaccines and chemotherapy or radiotherapy have demonstrated this potential advantage 
(Yu et al., 2003; Teitz-Tennenbaum et al., 2003; Song and Levy, 2005). The in vivo 
expansion and generation of mature DCs offers many other potential theoretical 
advantages over the traditional in vitro culturing of DCs. In vivo expansion of DCs has 
the potential to generate various distinct DC subsets with different immune functions in 
order to elicit an optimal immune response (Fong and Hui, 2002). Although the exact 
lineage from which DCs are derived remain controversial, there is growing evidence that 
DCs can be sub-classified into myeloid and lymphoid subsets (Ardavin et al., 1993; Wu 
et al., 1996; Sauders et al., 1996) and these may have synergistic roles in generating an 
effective immune response. In addition, DC expansion in vivo in lymphoid and non-
lymphoid organs could also greatly increase the chance of interaction with precursor T 
cells (Fong and Hui, 2002). It has also been reported that granulocyte monocyte- colony 
stimulating factor (GM-CSF)-treated mice generate a significant increase in DCs in the 
lymphoid and non-lymphoid compartments (Braun et al., 1999). This provides indirect 
evidence that DCs cultured in vitro are different from that in vivo and other presently 
unknown factors are critical for the generation of DC in vivo. Nonetheless, it is important 
to take note that concerns had been raised previously about the in vivo mobilization 
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method of DC-based immunotherapy as it has been shown that DCs from cancer patients 
are not only quantitatively defective but also qualitatively impaired due to tumor-induced 
inhibition of DC differentiation and maturation (Gabrilovich et al., 2004). Hence, in vivo 
generation of unprimed DCs may just result in an increase of immature non-functional 
DCs in cancer patients. Worse still, it has also been shown that increased mobilization 
and hence, numbers of immature DC may result in immune tolerance rather than produce 
an immunostimulatory effect. Thus, the effects of in vivo mobilization of DC may be 
counter-productive (Lutz and Schuler, 2002).   
It has recently been demonstrated by Wu et al., 2001 that the administration of the 
recombinant gene encoding hFlt-3L gene into mice could also result in the in vivo 
expansion of DCs. Subsequently, a follow-up study demonstrated that the use of 
pNGVL3-hFlex plasmid DNA to expand DCs in vivo could induce a potent tumor-
specific immune response when primed with a tumor peptide (Fong and Hui, 2002). In 
this study, mice primed with hFlt-3L gene and a tumor specific peptide were able to elicit 
an antigen-specific cytotoxic T-cell response which retarded tumor growth. A single 
injection of the plasmid DNA resulting in a peak elevation of DCs in various lymphoid 
and non-lymphoid organs 7 to 10 days post-immunization suggesting that this was the 
optimal time for antigen presentation. Hence, this study showed that fears that in vivo 
mobilization of immature DCs may be detrimental in malignancy is unfounded. This is 
with the caveat that an appropriate stimulus is present to prime naive DCs to mature.   
 
1.4 Photoimmunotherapy  
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PDT used in combination with other immunostimulatory agents or strategies also 
termed photoimmunotherapy have been recently reported in several studies (Jalili et al., 
2004; Castano et al., 2006). This combination approach can be broadly divided into 3 
categories ie. 1) PDT with microbial adjuvants 2) PDT and cytokine therapy and 3) PDT 
with regulatory T-cells and adoptive cellular therapies (Castano et al., 2006). 
PDT and microbial adjuvants. Agents derived from microbial stimulators of the 
innate immune system can be injected intra or peri-tumorally before, during or after PDT. 
These agents function as activators of TLRs or similar pattern-recognition molecules 
found on macrophages and DCs (Castano et al., 2006; Takeda et al., 2003). TLRs 
function as detectors of danger signals. Activation of TLR pathways induce nuclear 
transcription factor (NF)κβ which consequently results in the expression of several genes 
involved in immune system activation (Seya et al., 2003). Based on these observations, 
several studies were performed to test the effectiveness of combination therapy involving 
the administration of immunoadjuvants (potential TLR ligands) and PDT (Castano et al., 
2006).  Korbelik et al., 2001 demonstrated that PDT used in combination with a single 
dose of BCG was superior to PDT alone in treating subcutaneous EMT6 tumors in mice 
irregardless of the photosensitiser utilized. Photoimmunotherapy significantly increased 
the number of cured tumors and the number of memory T-cells in tumor draining lymph 
nodes as compared to PDT alone. In another study, schizophyllan (SPG) used in 
combination with Photofrin-mediated PDT of mice harboring SCCVII increased the 
tumor cure rate threefold as compared to PDT alone (Krosl and Korbelik, 1994). SPG is a 
fungal polysaccharide which is a potent inducer of humoral and cell-mediated immunity 
via macrophage dectin 1 receptor as well as TLR (Castano et al., 2006). After observing 
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that the complement system was activated during PDT, Korbelik et al demonstrated that 
tumor-localized treatment with zymosan, an alternative complement pathway activator 
could reduce the number of recurrent tumors after PDT (Korbelik et al., 2004). 
PDT and cytokine therapy. Another class of photoimmunotherapy involves the 
administration of cytokines in combination with PDT. A single dose of intravenously 
administered recombinant tumor necrosis factor (TNF)α was shown by Bellnier to 
potentiate Photofrin-mediated PDT of murine SMT-F adenocarcinoma (Bellnier, 1991). 
Others also demonstrated that localized tumor treatment with GCSF or GMCSF with 
PDT resulted in a significant reduction of tumor growth, increased survival of mice and 
even complete cure of mouse tumors (Golab et al., 2000; Krosl et al., 1996). 
PDT with regulatory T cells and adoptive cellular therapies. The 3rd category of 
photoimmunotherapy includes interventions designed to modify and augment the cellular 
arm of the adaptive immune system (Castano et al., 2006). This includes PDT combined 
with DC-based immunotherapy which is the subject of the present study. Recently, 
combination treatment of PDT with DC-based immunotherapy as a form of 
photoimmunotherapy has been shown to be an effective anti-tumor treatment for 
colorectal cancer and melanoma in murine models (Saji et al., 2006; Jalili et al., 2004). 
Theoretically, the unique mechanism of PDT-induced tumor destruction which not only 
mediates apoptotic and necrotic tumor cell death but also alters the tumor 
microenvironment through the release of proinflammatory cytokines such as TNF α, IL-1 
and IL-6 (Saji et al., 2006; Dougherty et al.,1998; Gollnick, 1997) creates an environment 
that favours DC maturation and antigen-loading (Engleman, 2004). One of the common 
reasons attributed to the limited clinical efficacy of DC-based immunotherapy is their 
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variable ability to induce a strong anti-tumor immune particularly cytotoxic T 
lymphocyte response which may be due to problems associated with tumor antigen 
selection and activation (Saji et al, 2006). Most of these clinical trials have included 
single or only a few tumor antigens to activate and load DCs in vitro whereas in vivo 
tumors potentially contain thousands of antigens. Hence, photoimmunotherapy with 
intra-tumoral DC injection theoretically overcomes this limitation as the activation and 
loading of DCs after photoimmunotherapy with intra-tumoral DC injection is in vivo. 
Two recent studies (Saji et al, 2006; Jalili et al, 2004) reporting on the outcome of 
photoimmunotherapy using PDT and DCs for malignancies were based on this 
hypothesis. In both these studies, DCs were harvested ex vivo and injected intra-
tumorally. Both studies found that combination therapy (photoimmunotherapy) induced a 
strong anti-tumor immunity which resulted in destruction of both the targeted tumor and 
tumors at distant sites (Saji et al., 2006; Jalili et al., 2004).  
 
1.5 Melanoma. 
Although malignant melanoma is extremely rare in Black and Asian populations, 
it is relatively more common in Caucasians. This is presumably due to the sensitivity of 
white skin to sun exposure (Markovic et al., 2007). Its incidence is reported to be 
increasing at a faster rate than any other cancer in the United States and Western 
European countries (Pilla et al., 2006). In the United States, it is presently the fifth most 
common cancer affecting men and the sixth most common cancer in women (Markovic et 
al., 2007). Malignant melanoma is a highly lethal disease, accounting for only 4% of all 
skin cancers but causing almost 80% of skin cancer deaths. A well-know feature of 
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malignant melanoma is that the tumor cells can spread haematogenously and lead to 
distant metastases. At the time of diagnosis, 80-85% of patients have stage I or II disease 
(local), 10-13% have stage III disease (regional) and 2-5% have stage IV disease (distant 
disease) (Balch et al., 2001). Several factors have been identified as important prognostic 
factors in melanoma including depth of invasion, ulceration, presence of microsattelites, 
satellites and in-transit metastases, lymph node involvement and distant metastases 
(Markovic et al., 2007). 
The treatment of choice for stage I to III melanoma is surgical excision. The 
choice of surgical margin is dependent on the depth of the tumor which has been shown 
to be an important prognostic factor in melanoma (Balch et al., 2001). Although, surgical 
resection is effective for early stage tumors, advanced stage melanoma ie. American Joint 
Committee on Cancer (AJCC) stage III and IV cancers are associated with a poor 
prognosis. Adjuvant systemic therapy such as levamisole, vaccines, interferon (IFN) and 
chemotherapy have been administered after surgical resection for high risk primary 
melanoma to reduce the risk of systemic disease recurrence and death (Verma, et al., 
2005). However, systemic review of numerous randomized trials do not demonstrate any 
significant overall survival benefit with any of these adjuvant therapies (Verma, et al., 
2005). 
Melanoma with distant metastases is associated with a median survival of 6 to 9 
months and the 5-year survival rates are reported to be in the range of 1 – 5% (Balch et 
al., 2001). This is especially so with regards to patients with advanced disease associated 
with cutaneous or subcutaneous metastases whom have an extremely poor prognosis. 
Presently, many of these patients are offered palliative treatment with intravenous 
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chemotherapy, isolated limb perfusion, interferon or IL-2 therapy (Naylor et al, 2006). 
However, palliative control of widespread cutaneous metastases is extremely difficult 
with currently available treatment modalities. Presently, the most widely used 
chemotherapeutic agent for melanoma is dacarbazine alone or in combination with other 
drugs (Pilla et al., 2006). These regimens have been reported to produce response rates 
ranging from 30 to 50% in Phase II trials. However in large Phase III randomized studies, 
chemotherapy has had limited impact on overall patient survival (Chapman et al., 1999). 
Similarly, while chemotherapy regimens in combination with systemic administration of 
cytokines such as IL-2 and IFN-α have produced promising results in terms of response-
rate and progression-free survival in early Phase II trials, subsequent Phase III studies 
have failed to demonstrate improvement in overall survival (Ridolfi et al., 2002; Keiholz 
et al., 2005). Due to the poor outcome of metastatic malignant melanoma to traditional 
chemotherapy, numerous systemic options such as immunotherapy have been 
investigated as possible alternative treatment options (Pilla et al., 2006).  
 
1.5.1 PDT for melanoma 
Although, PDT has been established as a therapeutic option for various primary 
and secondary skin malignancies, the use of PDT has been traditionally found to be of 
limited benefit in melanoma (Biel, 1996; Nowak-Sliwinska et al., 2006). This has been 
attributed to the presence of large amounts of light-absorbing melanin pigment that 
prevents light penetration into the tumor tissue. Hence, it was previously believed that 
only amelanotic melanoma such as melanoma of the iris respond satisfactorily to PDT 
(Favilla et al., 1991). Melanin are natural pigments found in many organisms and tissues 
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(Lim et al., 2004). The formation of melanin in human skin offers protection against UV 
light via 2 mechanisms. Firstly, it absorbs and scatters incident light. Secondly, melanin 
is also responsible for scavenging ROS such as superoxide anions, hydroxyl radicals and 
singlet oxygen and for inhibiting lipid peroxidation. Studies have demonstrated that there 
is good correlation between the degree of pigmentation and response to PDT (Nelson et 
al., 1988). Presently, it is also believed that the microevironment of melanoma tumors 
which may be hypoxic in vivo contributes to the ineffectiveness of PDT (Brurberg et al., 
2004). This is attributed to the fact that melanoma cells exhibit a high oxygen 
consumption due to respiration, melanogenesis and physicochemical interaction between 
oxygen and melanin (Pajak et al., 1980; Hopwood et al., 1985; Nowak-Sliwinska et al., 
2006).  
Most of the earlier studies studying the effect of PDT on melanoma utilized first 
generation photosensitizers such as Photofrin (Peeva et al, 1999; Pass, 1993) which 
activated light at a wavelength of 630 nm. The competition between the light absorption 
regions of melanin and these photosensitizers resulted in the poor yield of PDT-mediated 
melanoma destruction. However, in 1998, Haddad et al., 1998 conducted a study which 
demonstrated that PDT could be effective in the treatment of melanoma. They 
demonstrated that PDT using aluminium phthalocyanine decreased B16 melanoma cell 
viability in vitro. More importantly, PDT retarded the growth of B16 tumors and 
prolonged survival of mice inoculated with B16 melanoma. The authors further 
hypothesized that as melanin converts a large fraction of light into heat (Polla et al., 
1982), PDT could also cause tumor death via hyperthermia. This additive, synergistic 
effect of PDT and tumor hyperthermia was consistent with the findings demonstrated by 
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Leunig et al., 1994 in their study evaluating the effect of PDT-induced heating of 
melanoma in vivo. Subsequently, several others have confirmed that PDT using various 
photosensitizers can result in efficient tumor destruction of melanoma (Busseti et al., 
1999; Lim et al., 2004, Kolarova et al. 2007). 
The efficiency of PDT on melanoma has been shown to be dependent on the type 
of photosensitizer used (Peeva et al., 1999). Melanin absorbs light over broad spectrum 
with a peak absorption at about 335 nm. Its absorption of light decreases with longer 
wavelengths until its absorption of light is almost completely attenuated at wavelengths 
over 700 nm. Lim et al demonstrated efficient tumor destruction in vivo and in vitro of 
B16F10 melanoma cells with silkworm-pheophorbide a (Lim et al., 2004) This was 
attributed to its long wave-length of light absoprtion at 665nm. It is well-documented that 
the longer the light absorption wavelength of photosensitizers used the deeper the skin 
penetration (Marcus, 1990). In another interesting study, Nowak-Sliwinska et al., 2006 
compared the efficiency of PDT utilizing various photosensitisers against melanoma. 
They found that Verteporfin was superior to merocyanine C540 and photofrin II in 
achieving tumor control in vitro. They attributed this finding to the mechanism of tumor 
destruction of Verteporfin which strongly depended on the high yield of singlet molecular 
oxygen.   
Initial studies on the clinical use of PDT for skin metastases from melanoma 
yielded poor results with a clinical effect produced in only 20-30% of patients (Biel, 
1996; Feyh, 1996). However, subsequent clinical studies utilizing different 
photosensitizers produced more promising results. Sheleg et al., 2004 studied the effect 
of chlorin e6-mediated PDT on 14 patients with skin metastases. They found complete 
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regression in all 14 patients with 8 patients requiring only 1 session of PDT. There was 
also minimal toxicity observed with PDT treatment. Two patients developed pyrexia and 
rigors and 8 developed pain several days after PDT controlled with oral morphine. There 
were no major toxicities observed such as photodermatitis, renal or hepatic injury.  
 
1.5.2 Immunotherapy for melanoma 
 Interest in the use of immunotherapy for melanoma arose when observations from 
clinical and epidemiological studies revealed anecdotal cases of spontaneous regression 
of primary melanoma and that an increased incidence of melanoma occurs in the 
immune-suppressed (Euvrard et al., 2003). This was further confirmed by 
histopathological studies which demonstrated improved prognosis of malignant 
melanoma when the primary lesions were associated with T lymphocyte infiltrate 
(Clemente et al., 1996). The seminal work by van der Brugge et al in 1991, whereby the 
first human melanoma antigen recognized by CD+ T cells was cloned opened the door to 
numerous other studies whereby many other melanoma antigenic peptides were identified 
(Novellino et al., 2005). Subsequently, numerous immunotherapy regimes were 
formulated for advanced AJCC stage IV melanoma and evaluated in clinical trials. 
Broadly, the various vaccines for malignant melanoma can be classified into cell-based 
vaccines, peptide-based vaccines, DC-based vaccines, recombinant virus vaccines, 
plasmid or naked deoxyribonucleic acid (DNA) vaccines and vaccination with HSPs. 
Thus far, despite considerable investment of time and money in immunotherapy 
for melanoma, both first and second generation vaccines have failed to demonstrate 
superior clinical efficacy in large Phase III randomized trials over chemotherapy or even 
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best supportive care (Schadendorf et al., 2006; Rosenberg et al., 2004; Pilla et al., 2006). 
However, despite the wide gap between the results of highly promising preclinical studies 
and the poor efficacy of vaccines shown by clinical trials thus far, considerable effort to 
produce a clinically-useful vaccine continues. This is because the potential clinical 
applicability of vaccines in melanoma has been fully demonstrated (Pilla et al., 2006). 
The high immunological response rates demonstrated in clinical trials coupled with 
highly successful results in a limited number of patients have corroborated the possibility 
of successful immunotherapy in the treatment of melanoma. The challenge of successful 
immunotherapy in melanoma is to induce a clinically relevant immune response. 
Presently, it is believed that the inability of vaccines to induce a sufficient quantity and 
quality of anti-tumor cell response is responsible for its initial failures (Pilla et al., 2006). 
The challenge to generate an adequate qualitative T-cell response consists of the 
identification of a strong stimulus to induce an adequate anti-tumor T-cell response. PDT 
may be the answer to this challenge as it has been shown in numerous studies as 
discussed previously to result in strong anti-tumor T- cell immune response by activating 
both the innate and adaptive arms of the immune system.  Hence, interest has arisen on 
the combined use of PDT with immunotherapy (photoimmunotherapy) for the treatment 
of melanoma.  
 DC-based vaccination has been studied extensively in stage IV malignant 
melanoma. As melanoma-associated peptide antigens have been well-characterized, these 
have been utilized for pulsing DCs. Other cancer associated antigens including acid-
eluted tumor peptides, tumor lysates, messenger ribonucleic acid (mRNA) and tumor-DC 
hybrids have also been used (Proudfoot et al., 2007). An important Phase I trial 
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demonstrated that 13 of 18 patients generated an INF-γ T-cell immune response to at least 
2 melanoma peptides after four vaccinations with subcutaneous DC loaded with four 
melanoma peptides (Fay et al., 2006). In that study, the overall median survival of 
patients was 20 months (range, 2-83 months) and this was significantly higher for 
patients that mounted an immune response. This was especially so for those responding 
to more than 1 melanoma antigen. However, despite the success demonstrated with Phase 
II trials, Phase III trials have failed to demonstrate good melanoma tumor response to 
DC-based vaccines. A notable Phase III trial was conducted to compare the efficacy of 
autologous peptide-pulsed DCs with dacarbazine in metastatic melanoma utilizing a 
cocktail of class I and II-restricted peptides representing melanoma antigens.  After 
interim analysis of 108 patients, the study was closed early as there was no significant 
advantage of the DC arm versus the dacarbazine arm in terms of response rate (3.8% vs 
5.5%) and overall survival (Schadendorf et al., 2006).  
 The main reason for the disappointed results of immunotherapy for melanoma has 
been attributed to the presence of immune barriers at the level of the melanoma tumor 
microenvironment (Gajewski, et al., 2007). Two of the key evasive mechanisms which 
have been identified to confer tumor resistance to the effector phase of the anti-tumor T-
cell response are poor chemokine-mediated trafficking of effector cells and the action of 
negative regulatory pathways that inhibit T-cell function (Gajewski et al., 2007). Some of 
these negative regulatory pathways include T-cell anergy, suppression by regulatory T-
cells, action of inhibitory ligands and metabolic dysregulation (Gajewski et al., 2007). 
 
1.5.3 Photoimmunotherapy for melanoma   
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The first study conducted using DC-based photoimmunotherapy for melanoma 
was performed recently by Saji et al., 2006. The investigators found that PDT alone could 
not induce any tumor suppression in even very small 3mm diameter B16 melanoma cells 
(Saji et al., 2006). However, they subsequently demonstrated the superior potential of 
photoimmunotherapy using ATX-S10 Na(II)-PDT and intra-tumoral DC over PDT alone 
to treat local and systemic B16 melanoma cells in mice (Saji et al., 2006). This study was 
important as it not only demonstrated the ability of combination immunotherapy (intra-
tumoral DC injection) to enhance the anti-tumor effects of PDT but also that this 
synergistic effect of immunotherapy could be demonstrated in poorly immunogenic 
tumors (B16 tumors). 
More recently, a clinical study reported promising results on the palliative use of 
in situ photoimmunotherapy in 2 patients with advanced stage melanoma with cutaneous 
metastases. In that the study, PDT was performed using a near infrared (IR) 805 nm laser 
with intralesional injection of indocyanine green. Immunotherapy was administered via 
topical imiquimod a TLR agonist which has been reported to be effective against 
melanoma (Steinmann et al., 2000; Hesling et al., 2004; Vereecken et al., 2003). The 
study demonstrated that photoimmunotherapy was well-tolerated, could effectively clear 
local cutaneous and subcutaneous deposits and most importantly demonstrated beneficial 
systemic anti-tumor effects such as regression of lung metastases. 
  
1.6 Scope of study 
In this study, we hypothesize that PDT combined with the in vivo expansion of 
DCs may induce anti-tumor immunity. As such this study was designed to determine if 
 34
photoimmunotherapy via the combination of HY-PDT with the in vivo expansion of DCs 
using pNGVL3-hFlex plasmid DNA was effective in inducing antitumor immunity.  
 
The objectives of this study are to: 
1. Evaluate if HY-PDT was effective in inducing tumor destruction of murine B16 
melanoma  
2. Determine the appropriate HY and light dose for effective PDT of B16 melanoma 
3. Establish the predominant mode of cell death after PDT of B16 tumor and if 
incubation period had an effect on this 
4. Compare the anti-tumor effect of photoimmunotherapy versus PDT alone versus 
control on B16 melanoma (primary tumor model) 
5. Determine if photoimmunotherapy generated an effective anti-tumor vaccine 
compared to PDT alone and control 
6. Evaluate if photoimmunotherapy retarded the growth of a large and small 
established contralateral tumor compared to PDT alone and control (metastatic 
model) 
7. Ascertain if the effect of photoimmunotherapy was tumor specific 
8. Determine if the splenocytes of photoimmunotherapy treated mice harbored 

























2.1 Cell culture 
Murine B16 melanoma cell line (original source - American Type Culture 
Collection) and RMA lymphoma parental cell line (originally from Dr Acres, Transgene, 
Strasbourg, France) were used in the study. Both B16 melanoma and RMA cell lines 
were gifts from Prof. K.M. Hui, Division of Cellular and Molecular Research, National 
Cancer Centre, Singapore (Fong and Hui, 2002). Both cell lines were cultured in Roswell 
Park Memorial Institute (RPMI) 1640 supplemented with 10% fetal bovine serum (FBS; 
Hyclone, Logan, UT, USA), 100 IU/ml penicillin, 100 μg/ml streptomycin, 292 μg/ml L-
glutamine (GIBCOBRL, Life Sciences, NY, USA) and 1 mM sodium pyruvate (JRH 
Biosciences, KS, USA). These were maintained in an atmosphere of 5 % CO2 at 37ºC. 
 
2.2 Mice 
Female C57BL/6 mice, 8-12 weeks of age were used in the experiments. These 
were purchased from the Animal Laboratory Unit of the National University of 
Singapore. The animals were housed in the National Cancer Centre Animal Holding Unit 
and were fed with pellets (Glen Forrest stockfeeder, Australia). The animals were 
sacrificed via delivery of 100% carbon dioxide. They were euthanized when the tumor 
diameter exceeded 30 mm or when they were in distress, which ever event occurred first. 
All experiments were performed in compliance with the National Advisory 
Committee for Laboratory Animal Research Guidelines in Singapore and all procedures 
were approved by the Institutional Animal Care and Use Committee, Singhealth 
Singapore in accordance with international standards. 
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2.3 Tumor model 
 The caudal half of the mice was shaved and 0.5 x 106 cells (B16 cells or RMA 
cells) suspended in 100 μL Hanks Buffered Salt Solution (HBSS) were injected 
subcutaneously into the lower right or left flank of the mice. The cells were counted using 
a hemocytometer. Tumor growth was subsequently monitored. The tumors were 
measured in 3 dimensions: length, breath and thickness using an electronic Vernier 
caliper. The tumor volumes were subsequently estimated according to the formula: tumor 
volume (mm3) = π/6 x length x breath x thickness.  
 
2.4 Photosensitizer  
HY, a photosensitizer with a maximum absorption of 590 nm (Du et al., 2003) 
was obtained from Molecular Probes (Eugene, OR, USA). This was prepared as a stock 
solution of 1mg/ml in dimethyl sulfoxide (DMSO) and stored at -20°C in the dark. The 
photosensitizer was diluted in phosphate buffer saline (PBS) before injection into mice. 
 
2.5 Light source 
A broadband halogen light source (Zeiss KL1500), fitted with a customized 560-
640 nm band-pass filter (46152, Edmund Scientific Inc.) was used as the light source. A 
power meter (Laser check, Coherent, USA) was used to quantitate light intensities.  
 
2.6 Photodynamic treatment of tumors 
The mice were restrained in a self-made restrainer and 5 mg/kg of hypericin in 
0.1ml PBS were administered parenterally via the tail veins of the tumor-bearing mice. 
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The mice were subsequently housed in cages covered with aluminium foil and protected 
from surrounding light. Subsequently, prior to photodynamic therapy; the mice were 
anesthetized with 1:1 cocktail of diazepam (5 mg/ml) and ketamine (50 mg/ml) at a dose 
of 1 ml/kg given intraperitoneally. They were then placed in a specially designed holder 
and only the tumor-bearing region to be treated with light was exposed. 
 
2.7 Plasmid DNA 
The PNGVL3-hFlex plasmid containing the extracellular domain (secreted form) of the 
human Flt-3L gene was originally obtained from the Vector Core Laboratory at the 
University of Michigan (Ann Arbor, MI, USA) and has been described previously 
(Lyman et al., 1994). These were also kindly provided by Professor K. M. Hui. Plasmid 
purification was performed with the QIAGEN® plasmid kit (QIAGEN N.V., 
Netherlands) as described in the manufacturer’s handbook (QIAGEN® Plasmid 
Purification Handbook, 2003). These were delivered in vivo via hydrodynamic-based tail 
vein injection (Liu et al., 1999). Briefly 10 μg of DNA was diluted in 1.5-2 ml of 
sterilized 0.9% NaCl solution and injected into the tail vein over 10 s using a 271/2 g 
needle (Wu et al., 2001). 
 
2.8 Transmission Electron Microscopy (TEM) 
i) Fixation of tissues 
The tissues were immersed in cold 2% paraformaldehyde and 3 % glutaraldehyde in 0.1 
M sodium phosphate buffer (pH 7.4) and fixed for a duration of 4 hours. The specimens 
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were subsequently rinsed 3 times with 5% sucrose solution in 0.1 M phosphate buffer 
(pH 7.4). 
ii) Osmication 
The specimens were cut into small pieces under a dissecting microscope (Nikon SMZ-1, 
Japan). These were fixed in 1% osmium tetroxide in phosphate buffer containing 1.5% 
potassium ferrocyanide for 2 hours in a fume cupboard. Specimens, were then washed 
twice with deionized water. 
iii) Dehydration and embedding 
Dehydration was performed with an ascending series of ethanol. Specimens were 
immersed in 25% ethanol for 5 minutes, and in 50%, 75%, 95% and 100% ethanol for 10 
minutes each, before processing. They were subsequently processed in absolute acetone 
for 10 minutes with 2 changes. A 100% acetone and araldite mixture (1:6) was used to 
infiltrate the specimens for 2 hours and before 3 changes of fresh resin. The specimens 
were incubated in an oven at 40 °C, 45 °C and 50 °C for 1 hour during each change. 
Finally, the tissues were embedded in dried araldite capsules and allowed to polymerize 
in an oven at 60 °C for 24 hours.   
iv) Trimming and ultra-thin sectioning 
 The capsule blocks were trimmed with an electrical trimmer to remove excess portions 
of araldite. Subsequently, the capsule blocks were cut with an ultramicrotome (Ultracut 
E, Reichert-Jung 200M) to obtain sections of 1 μm. The sections were mounted on glass 
slides stained with 1% toluidine blue and examined under the light microscope (Leitz 
Aristoplan). Subsequently, ultra-thin sections (0.1 μm) were cut and a fine hair brush was 
than used to place the ultra-thin sections on G100 formvar-coated copper grids. 
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v) Staining of sections 
All sections were stained with 2% uranyl acetate and lead citrate. The grids bearing 
sections were put on drops of saturated uranyl acetate for 10 minutes. These were than 
washed with deionized water. After drying, they were allowed to float on drops of lead 
citrate for 8 minutes. The grids were than rinsed again with deionized water and dried. 
vi) Examination under TEM 
A TEM (Philips CM120 Biotwin, Oregon, USA) was operated at an accelerating voltage 
of 60-80 KV and was used to examine the tissue sections.  
 
2.9 In vivo experiments 
2.9.1 Effective PDT of B16 melanoma in C57BL/6 mice 
Aim: To determine the light dose for effective PDT without causing mouse toxicity 
As no previous study has been published on PDT with HY on B16 melanoma tumors, 
preliminary experiments had to be conducted to identify the effective drug dose and light 
setting for the destruction of B16 tumors in vivo without major toxicity to the mouse. 
[based on a previously published protocol (Du et al., 2003)]. B16 cells (0.5 x 106 cells per 
mouse) in 100 μL HBSS were injected subcutaneously into the lower right flank of pre-
shaven C57BL/6 mice. Between days 8 to 10 when the tumors were established, the mice 
were administered with 5 mg/kg of HY via tail vein injection followed by light irradiation 
of the tumor after an incubation period of 1 or 6 hours later. The 2 incubation periods of 
the drug (1 and 6 hours) were selected as it has been shown previously that cell death 
occurred predominantly via apoptosis at 1 hour and via necrosis at 6 hours (Du, 2004) 
after HY-PDT. These 2 modes of cell death may have an effect or the immune response 
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generated by PDT. PDT was than administered with a HY dose of 5 mg/kg and the light 
dose was increased step-wise from 30, 60, 90 to 120 J/cm2 for each incubation period (1 
or 6 hours) respectively. Three mice were assigned to each of the 8 groups. The tumors 
on the mice were subsequently observed and the treatment was considered effective when 
the tumor was completely destroyed with no gross tumor visible (usually after 3 days). 
 
2.9.2 Effect of the mode of cell death after HY-PDT and if incubation period (1 vs 6 
hours) influenced the mode of cell death 
Aim: To determine if the mode of cell death and if incubation period has an effect on the 
mode of cell death after PDT of B16 tumor 
Three mice were each assigned to 2 groups (incubation period 1 hour and 6 hours). B16 
tumor cells were than injected into both flanks of all 6 mice. Between days 8 to 10, when 
the tumors were established, PDT was than administered to the tumors in the right flank. 
The control group consisted of the tumors in the left flank.  At 1 hour or 6 hours after 
PDT the mice were sacrificed and the tumors were harvested and prepared for electron 
microscopy. The specimen slices were studied to determine if the mode of cell death was 
predominantly via apoptosis or necrosis for the 2 incubation periods. 
  
2.9.3 Growth curve of B16 and RMA tumor model 
Aim: To determine the growth curve of B16 and RMA tumor model  
B16 and RMA tumors cells were inoculated into the right flank of mice and the growth of 
these tumors were measured. Three mice were used for each tumor model. 
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2.9.4 Effect of photoimmunotherapy and PDT in a B16 primary tumor model 
Aim: To determine and compare the effect of photoimmunotherapy versus PDT alone 
versus control on a B16 primary tumor model. 
PDT was administered as previously described (2.9.1). With regards to 
photoimmunotherapy; on day 0, B16 tumor cells were injected into the lower right flank 
of the mice. The plasmid DNA was injected into the tail vein on day 2 and on day 9, PDT 
was administered. An interval of 7 days after injection of the plasmid DNA was chosen 
before PDT as it has been demonstrated previously that this was the time interval 
whereby the maximum cytotoxic T-cell response could be observed (Fong and Hui, 
2002). The mice were divided into 7 groups (5 to 8 mice per group) for comparing the 
effects on tumor growth. The two control groups comprised of Group 1 which had tumor 
cells inoculated but no administration of plasmid or PDT and Group 2 where plasmid 
alone was injected without photodynamic therapy. There were 2 PDT groups; Group 3 
and Group 4 whereby tumor cells were inoculated and PDT was administered at 
incubation periods of 1 hour and 6 hours but no plasmid was injected. Group 5 and 6 
were the photoimmunotherapy groups, both intravenous plasmid injection and PDT were 
performed at incubation periods of 1 hour and 6 hours respectively. The tumor growths 
were subsequently monitored and compared.  
 
2.9.5 Effectiveness of photoimmunotherapy in generating an anti-tumor vaccine 
Aim: To determine if photoimmunotherapy generated an effective anti-tumor vaccine.  
PDT and photoimmunotherapy were administered as previously described. However, this 
time the mice were challenged with a second tumor in the left flank at day 15 after the 
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initial tumor inoculation (5 days after PDT). The time interval of 5 days was arbitrarly 
selected to presumably allow sufficient time for an adequate immune memory response. 
The mice were divided into 5 groups and compared (minimum of 5 mice per group): 1 
control group with no treatment (Group 1), 2 PDT groups with incubation of 1 and 6 
hours (Group 2 and 3) and 2 photoimmunotherapy groups with incubation of 1 hour and 
6 hours (Group 4 and 5). The tumors in the left flank were then measured serially and 
compared. As no significant difference in terms of anti-tumor effect was observed 
between the 2 incubation periods, the 1 hour incubation period was used in subsequent 
experiments for convenience.  
 
2.9.6 Effect of photoimmunotherapy on a contralateral tumor (metastasis model) 
Aim: To determine if photoimmunotherapy retarded the growth of an established 
contralateral tumor (Small and large metastasis model) 
Treatment protocols were performed as previously described.  
For the small metastasis model, mice were inoculated with a second tumor (metastasis) in 
the left flank on day 4 after the primary tumor was inoculated to simulate tumor 
metastasis. The mice were divided into 3 groups (minimum of 5 mice per group): Group 
1 (control group) with no treatment, Group 2 (PDT alone) and Group 3 
(photoimmunotherapy). The volumes of tumors in the left flank were then monitored. 
For the large metastasis model, the second tumor (left) was inoculated on the same day as 
the primary tumor (right). PDT was administered at day 14. The mice were divided into 3 
groups (minimum of 5 mice per group): Group 4 (control group) with no treatment, 
Group 5 (PDT alone) and Group 6 (photoimmunotherapy group). We selected the tumor 
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implantation metastatic model instead of a lung metastasis model as this model would 
allow tumor metastases to be reproduced more consistently as compared to the 
unpredictable number and size of metastases in the lung metastasis model. Furthermore, 
the response of tumor metastases to treatment in the implantation model would be easier 
to quantify (by measuring tumor size) as compared to the lung metastatis model.  
 
2.9.7 Tumor specificity 
Aim: To determine if the effect of photoimmunotherapy was tumor specific. 
PDT and photoimmunotherapy were administered as previously described 2.9.5. 
However, this time the mice were challenged with a different second tumor (RMA) in the 
left flank at day 15 after the initial tumor inoculation (5 days after PDT). The mice were 
divided into 3 groups and compared (minimum of 5 mice per group): 1 control group 
with no treatment (Group 1), 1 PDT groups with incubation of 1 hour (Group 2) and 1 
photoimmunotherapy groups with incubation of 1 hour (Group 3). The RMA tumors in 
the left flank were then measured serially and compared. 
 
2.9.8 Adoptive immune transfer 
Aim: To determine if the splenocytes of photoimmunotherapy treated mice harbored 
immune cells that could be used to generate an effective tumor vaccine.  
Mice with B16 tumors were treated with photoimmunotherapy as before and euthanized 
at 5-7 days after PDT. The spleens were harvested and mashed in a plate. Splenocytes 
were obtained after the mashed spleen products were passed through a cell strainer and 
centrifuged. Before injection into mice, the red blood cell component of the splenocytes  
 45
were lysed using tris-buffered ammonium chloride.  The cells were counted and 5 x 107 
splenocytes were infused i. v. into 2 groups of mice. The control group was composed of 
mice inoculated with B16 in the right flank and RMA on the left flank. The treatment 
group (adoptive transfer) was also composed of B16 in the right flank and RMA in the 
left flank but with splenocytes injected i.v. at day 2.   
   
2.10 Statistical analyses 
All statistical analyses were conducted using the computer programme Statistical 
Package for Social Sciences for Windows, version 10.0 (SPSS Inc, Chicago, IL, USA) 
and Microsoft Excel 2003. Graphs were generated using Microsoft Excel. Results were 
expressed as mean ± SEM and unpaired 2 tailed t-tests were used to compare means. All 



































3.1 Effective PDT of B16 tumor 
PDT treatment was administered to the mice in escalating doses from 30, 60, 90 to 120 
J/cm2 with incubation periods of 1 and 6 hours. Effective tumor destruction without 
toxicity to the mice was grossly found only when PDT was performed with a HY dose of 
5 mg/kg and 120 J/cm2 light irradiation (100mW/cm2 x 25 minutes) after both 1 and 6 
hours incubation (Figure 2). There was minimal or no visible effect when doses of 30, 60, 





Figure 2A. Photograph of female C57BL/6 mouse with established B16 tumor 9 days 













Figure 2B. Photograph of female C57BL/6 mouse demonstrating the destroyed B16 






3.2 Mode of tumor cell death after HY-PDT  
The EM appearance of an untreated B16 tumor cell from the control group is 
demonstrated in Figure 3. HY-PDT of B16 tumors was performed with a HY 
concentration of 5 mg/kg and light dose 120 J/cm2 at an incubation period of 1 and 6 
hours. The predominant mode of tumor cell death was necrosis and this was regardless of 
the incubation period (Figure 4).  Only a small proportion of cells demonstrated some 
























Figures 3A and B. Electron photomicrogram. Control: tumor cells were intact with 





Figure 4. Electron photomicrogram of the tumor cells after PDT. The cells have mainly 
undergone necrosis displaying loss of integrity of the cell membrane, vacuolation, 
disintegration of cytoplasm and absence of apoptotic nuclear changes. A. B16 cells 
demonstrating features of necrosis after HY-PDT at incubation of 1 hour. B. B16 cells 









Figure 5. Electron photomicrogram: Some cells demonstrating secondary nucleus with 










3.3 Growth curve of B16 and RMA tumor model 
The growth curves of B16 murine melanoma and RMA murine lymphoma tumors in 
mice following inoculation of 0.5 x 106 cells subcutaneously. Both tumors demonstrate a 
exponential increase in tumor volume with rapid tumor growth at approximately 12 to 15 
days after tumor inoculation (Figures 6 and 7). The tumors were grossly visible at 7 to 10 
days with mean tumor volumes of about 40 mm3 and PDT treatment in subsequent 
experiments was administered during this time interval. The tumor volumes were 
estimated by measuring the tumor length, breath and thickness and calculated according 
to the formula: tumor volume (mm3) = π/6 x length (mm) x breath (mm) x thickness 
(mm). 
 
Figure 6. Growth curve of B16 murine melanoma tumors after subcutaneous injection of 
approximately 0.5 x 106 cells. Values were represented as mean ± SE of 3 animals. 

























Figure 7. Growth curve of RMA murine lymphoma tumors after subcutaneous injection 

























3.4 Effect of photoimmunotherapy and PDT in a B16 primary tumor model 
There was no difference in the tumor growth curves when both control groups (Groups 1, 
no PDT or plasmid administered and 2, no PDT but plasmid administered) were 
compared. In fact, the tumor growth curves were almost mirror images of each other 
(Figure 8). Similarly, the growth curves of the 2 PDT groups (Groups 3, incubation 
period 1 hour and 4, incubation period 6 hours) (Figure 9) and the 2 photoimmunotherapy 
groups (Groups 5, incubation period 1 hour and 6, incubation period 6 hours) (Figure 10) 
were similar with no statistical difference. The growth curves of the control, PDT and 
photoimmunotherapy groups were then plotted together in the same graph and compared.   
This demonstrated that both the PDT group and photoimmunotherapy groups was 
effective in inhibiting primary tumor growth (Figure 11). Effective gross tumor 
destruction was demonstrated with both methods. Both the PDT and 
photoimmunotherapy groups were superior to the control group in retarding B16 tumor 
growth. However, photoimmunotherapy was not superior when compared with PDT 















Figure 8. Comparison between the growth curves of B16 tumor in the 2 control groups 
(Group 1, no PDT or plasmid administered and Group 2, no PDT but plasmid was 
administered). There was no statistical difference between the 2 curves. The P-value at 
day 10, 13, 16, 18, 20 and 23 were .908, .353, .998, .590, .461, .165 respectively. Values 
































Figure 9. Comparison between the growth curves of B16 tumor in the 2 PDT groups 
(Group 3, incubation period 1 hour and Group 4, incubation period 6 hours). There was 
no statistical difference between the 2 curves. The P-values were .736, .431, .519, .398, 
.379, .782, .701, .836, .979, .637 at day 10, 13, 16, 18, 20, 23, 25, 27, 30 and 33 
































Figure 10. Comparison between the growth curves of B16 tumor in the 2 
photoimmunotherapy groups (Group 5, incubation period 1 hour and Group 6, incubation 
period 6 hours). There was no statistical difference between the 2 curves. The P-values 
were .100, .877, .703, .938, .862, .526, .578, .598, .910 and .682 at day 10, 13, 16, 18, 20, 





























Figure 11. Comparison between the growth curves of B16 tumor in the control (Groups 1 
and 2) versus PDT (Groups 3 and 4) versus photoimmunotherapy group (Group 5 and 6). 
Both the PDT and photoimmunotherapy groups were significantly superior to the control 
group in retarding tumor growth. The P-values were .914, .007, .003, <.001, <.001, <.001 
and .242, .004, .003, <.001, <.001, <.001 at day 10 to 25 respectively. However, there 
was no statistical difference between the growth curves of the PDT versus the 
photoimmunotherapy group. P-values were .395, .836, .737, .595, .972, .368, .580, .771, 
.633 and .301 at days 10 to 33 respectively. Values are represented by mean ± SE of at 
least 10 animals. 
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3.5 Effectiveness of photoimmunotherapy in generating an anti-tumor vaccine 
The mice were challenged with inoculation of a second B16 tumor in the opposite flank 
(left side).There was no difference in the second tumor growth curves between the 2 PDT 
groups (Group 2, 1 hour incubation period and Group 3, 6 hours incubation period) 
(Figure 12) and between the 2 photoimmunotherapy groups (Figure 13). However, when 
the second tumor growth curves of the control (Group 1), PDT alone group (Groups 2 
and 3) and photoimmunotherapy group were compared (Groups 4 and 5), mice with 
tumors treated with photoimmunotherapy were more resistant to a second tumor 
challenge as compared to PDT treated mice and mice with no treatment respectively 
(Figure 14). Mice in the PDT alone treated group seemed to be more resistant than the 
control to the second tumor challenge although this was not statistically significant. 








































Figure 12. Comparison between the growth curves of the second B16 tumor (left side) in 
the 2 PDT groups (Groups 2, 1 hour incubation period and 3, 6 hours incubation). There 
was no statistical difference between both curves. On the 7th, 9th, 12th, 14th, 16th and 19th 
day, the P-value was .664, .953, .920, .608, .690 and .065 respectively. Values are 



































Figure 13. Comparison between the growth curves of the second B16 tumor (left side) in 
the 2 photoimmunotherapy groups (Groups 4, 1 hour incubation period and 5, 6 hours 
incubation). There was no statistical difference between both curves. On the 7th, 9th, 12th, 
14th, 16th, 19th and 22nd day, the P-value was .731, .949, .261, .736, .436, .026 and .098 












Figure 14. Comparison between the growth curves of the second B16 tumor (left side) in 
the control (Groups 1) versus PDT (Groups 2 and 3) versus photoimmunotherapy group 
(Groups 4 and 5). The photoimmunotherapy group was significantly superior to both the 
control group, P-value on 7th, 9th, 12th, 14th, 16th and 19th day were <.001 and PDT group, 
P-value on 7th, 9th, 12th, 14th, 16th and 19th day were <.001, .001, <.001, <.001, <.001 and 
<.001 respectively in retarding tumor growth. The PDT group appeared to be superior to 
the control group but this was not statistically significant, P-values were .370, .614, .509, 
.512, .253 and .004 on the 7th to 19th day, respectively. Values are represented by mean ± 
SEM of at least 5 animals. 
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3.6 Effect of photoimmunotherapy on a preexisting contralateral tumor (metastatic 
model) 
The results showed that photoimmunotherapy conferred systemic antitumor effects 
against B16 melanoma cells. As demonstrated in Figure 15, the growth of the 
contralateral tumor was significantly suppressed compared to the 2 control groups (PDT 
and no treatment). However, when the pre-established tumor was large (Figure 16), there 










































Figure 15. Small metastasis model. Comparison between the growth curves of the 
second B16 tumor (left side) in the control (Groups 1) versus PDT (Groups 2) versus 
photoimmunotherapy group (Group 3). The photoimmunotherapy group was significantly 
superior to both the control group, P = .53, <.001, <.001, <.001, <.001 and PDT group, P 
= .29, <.001, <.001, <.001, <.001 at day 7, 9, 12, 15 and 18 respectively in retarding 
tumor growth. There was no difference between the tumor growth curve of the PDT 



































Figure 16. Large metastasis model. Comparison between the growth curves of the 
second B16 tumor (left side) in the control (Groups 4) versus PDT (Groups 5) versus 
photoimmunotherapy group (Group 6). The photoimmunotherapy group was not superior 
to both the control group and PDT group in retarding tumor growth P > .05. Values are 









3.7 Tumor specificity. 
This experiment confirmed the tumor-specific nature of photoimmuntherapy. Although 
previously, photoimmunotherapy was effective in retarding the growth of the second B16 
tumors, it did not demonstrate any effect on the second RMA tumor. There was no 
significant difference in the growth curves of RMA tumors in the control, PDT or 




Figure 17. Effect of PDT, photoimmunotherapy  























Figure 17. Tumor specificity. There was no significant difference in tumor growth 
between RMA tumors in the control group (Group1), PDT group (Group 2) and 




3.8 Adoptive immune transfer 
The results showed that adoptive transfer of primed splenocytes failed to result in growth 
retardation of B16 tumors. The B16 tumor growth curves were similar with or without 
the injection of primed splenocytes (Figure 18). As expected, there was no significant 






Figure 18. There was no significant difference between the growth curves of B16 tumor 
cells with and without adoptive transfer. The P-values on the 6th, 8th, 12th, 15th and 18th 
days post inoculation were .198, .223, .609, .004, .517 respectively. Values are 
represented by mean ± SEM of at least 5 animals. 
 

































Figure 19. Not unexpectedly, there was also no difference between the growth curves of 
the RMA tumor before and after the adoptive transfers of B16-primed T lymphocytes. 














































4.1 PDT in melanoma 
Presently, most researchers regard the role of PDT in the treatment of melanoma 
as limited (Biel, 1996) as traditionally, it has been well-documented that PDT alone is 
ineffective against melanoma (Biel, 1996; Schoenfeld et al., 1994; Saji et al., 2006). The 
large amounts of light-absorbing melanin pigment that prevents light penetration into the 
tumor tissue has been proposed as the reason behind this phenomenon. Previous studies 
on PDT using ATX-S10 Na (II) and 5-ALA with light of wavelengths more then 600 nm 
demonstrated the resistance of these tumors against PDT (Saji et al., 2006; Schoenfeld et 
al, 1994). However, others have confirmed that PDT using various photosensitizers can 
result in efficient tumor destruction of melanoma (Busseti et al., 1999; Lim et al., 2004, 
Kolarova et al. 2007). The present study confirms the findings that PDT can be effective 
against melanoma if higher light doses than usual are utilized. To the best of our 
knowledge this is the first study to date to demonstrate the ability of HY-PDT to produce 
tumor destruction in murine melanoma.  
In this study by using a higher light dose of 120 J/cm2, gross B16 tumor 
destruction as shown in Figure 2B could be produced even in tumors of 10 mm in 
diameter. These light doses were twice of that (60 J/cm2) used in a previous study on the 
effect of HY-PDT on HK1 and CNE-2 nasopharyngeal cancer cells (Du et al., 2003). 
Importantly, these high light doses used were not toxic to the mice which survived weeks 
after PDT treatment.  Interestingly, the wavelength of light used in our study was 580 nm 
which was shorter than that used in previous studies on PDT for melanoma. Melanin 
absorbs light over a broad-sprectum of wavelengths demonstrating maximal absorption at 
a wave-length of 335 nm. Its ability to absorb light decreases logarithmically as the 
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wavelength increases till almost negligible levels for light with a wavelength longer than 
700 nm. Hence, theoretically, PDT utilizing light with a longer wavelength should 
demonstrate better penetration through melanin pigment. The present observation 
suggests that wavelength alone (and hence, light penetration alone) may not be the sole 
determinant of effective PDT for melanoma and that other biochemical products which 
may be activated during PDT may be important for inhibiting or activating tumor 
destruction. Very recently, investigators from Germany have demonstrated that the 
expression of heme oxygenase 1 (HO-1) is at least partly responsible for the resistance of 
melanoma to ALA-PDT (Frank et al., 2007). The inactivation of HO-1 by gene silencing 
resulted in an approximately 50% increase in the tumor cell death rate after ALA-PDT in 
melanoma. Further studies, are needed to determine the model of tumor destruction of 
melanoma after HY-PDT. 
 
4.2 HY-PDT induced cell death 
The mode of HY-PDT mediated cell death (and PDT in general) may vary from 
both necrosis to apoptosis or both (Ali et al., 2002; Thong et al., 2006). The mode of cell 
death after PDT is influenced by several factors including photosensitiser dose, tumor 
type, light dose, light-fluence rate, drug-light interval, oxygen concentration and 
intracellular localization of photosensitiser (Thong et al, 2007). In general, most studies 
demonstrate that the mode of cell death shifts from apoptosis to necrosis when HY 
concentration and light dose is increased (Vantieghem et al., 2001; Kamuhabwa et al., 
2001). Cell type also has an important influence on the mode of cell death (Wyld et al., 
2001). For example, in a study analyzing the effect of HY-PDT in HK1 NPC cell lines, 
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PDT only induced necrosis irrespective of dose  (Du, 2004). Agostinis et al., 2002 found 
that malignant cells often had an impaired ability to undergo apoptosis. Some 
investigators believe that the extent of oxidative injury determines the mode of cell death 
(Girotti et al., 2001; Fiers et al., 1999). Less extensive oxidative damage that exceeds the 
repair capacity of the cell is likely to trigger apoptosis whereas more extensive damage 
which leads to membrane lysis would induce necrosis. Hence it is likely that cells more 
susceptible to oxidative stress such as HK1 are more likely to undergo necrosis rather 
than apoptosis (Du, 2004). 
This is the first study investigating the use of HY-PDT in B16 melanoma cell 
lines in vivo. The results demonstrated that at a HY dose of 5 mg/kg and light dose of 120 
J/cm2, the mode of cell death was predominantly via necrosis with only a minor degree of 
apoptosis. The results in this study was similar to that of the study on nasopharngeal 
carcinoma cells conducted by Du et al. that the anti-tumor HY-PDT effects were similar 
after drug incubations of 1 hour and 6 hours (Du, 2004). In that study, it was 
demonstrated that at 1 hour incubation, HY concentration was maximal in plasma and the 
mode of tumor destruction was vascular-mediated resulting in cell death mainly 
apoptosis. At 6 hours incubation HY concentration was maximal in the tumor and the 
mode of cell death was mainly via necrosis. However, these observations were only 
applicable to CNE-2 cells whereas for HK-1, the mode of cell death was predominantly 
via cell necrosis irrespective of PDT dose or incubation period. The results from the 
present study also demonstrated that regardless of the incubation period tumor cell death 
of B16 melanoma occurred mainly via necrosis. These findings emphasize the important 
influence of tumor cell type on the mode of cell death (Wyld et al., 2001).  The findings 
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were also consistent with those demonstrated by other investigators that the mode of cell 
death of melanoma cells after PDT were predominantly that of necrosis (Lim, et al., 
2004). However, it is important to note that the localization of HY after administration 
was not analyzed in this study and it is possible that the pharmacokinetics and dynamics 
of the drug maybe different in the present model from the NPC model. Also, as the mode 
of cell death was not specifically studied with various drug and light dosages, it may be 
entirely possible that apoptotic cell death of B16 melanoma can still be induced with HY-
PDT.  
Presently, it is controversial whether necrosis or apoptosis serves as a superior 
source of tumor-associated antigens for the activation of DCs (Albert et al., 1998; Sauter 
B et al., 2000; Rovere et al., 1998). However, evidence from the study by Gollnick et al 
suggested that cell death via both necrosis and apoptosis induces the most effective anti-
tumor response compared to either alone hence the superiority of PDT-generated vaccine 
over UV and ionizing radiation generated vaccines (Gollnick et al., 2002). Nonetheless, 
the relationship between mode of tumor cell death and efficiency of induction of the 
immune response remains unclear. Many studies examining this relationship by non-PDT 
treatment modalities both in vivo and in vitro have produced conflicting results (Magner 
and Tomasi, 2005; Bartholomae et al., 2004). Some reports have demonstrated that 
apoptotic cells are superior to necrotic tumor cells in inducing an immune response 
(Scheffer et al., 2003; Shaif-Muthana et al, 2000). On the other hand, others have shown 
that modalities inducing predominantly tumor cell necrosis are actually superior at 
activating the immune system as compared to methods causing predominantly apoptosis 
(Zitvogel et al., 2004; Melcher et al., 1999). After tumor cell necrosis, cytosolic contents 
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spill out to the extracellular space through the damaged plasma membranes and induce an 
acute inflammatory response. Host leukocytes are attracted to the tumor and potentiate 
the immune response possibly by increased antigen presentation. The present study 
suggests that tumor cell death occurring predominantly via necrosis can induce an 
effective immune response after photoimmunotherapy but not PDT alone. Further studies 
are needed to determine if apoptosis alone or a combination of apoptosis and necrosis 
will generate a more effective immune response.  
 
4.3 Photoimmunotherapy with DC-based vaccines 
The combination of PDT with DC-based vaccines or photoimmunotherapy has 
not been well-studied (Gollnick et al., 2002; Jalili et al., 2004; Saji et al., 2006). The first 
study to demonstrate the ability of PDT to enhance tumor cell immunogenicity and to 
generate an effective tumor vaccine was conducted by Gollnick et al., 2002 on murine 
EMT6 and P815 tumor models. They successfully demonstrated that PDT-treated tumors 
were highly immunogenic and PDT-generated lysates resulted in highly effective 
vaccines in the absence of an adjuvant (Gollnick et al., 2002). In that study, PDT-
generated tumor lysates formed potent vaccines which were superior to tumor vaccines 
generated by UV or ionizing irradiation. The authors postulated that the unique 
mechanism of PDT-mediated cell death which resulted in both apoptosis and necrosis as 
opposed to the predominantly apoptotic cell death after UV treatment and predominantly 
necrotic cell death after ionizing radiation could be the reason why PDT-treated tumors 
were more immunogenic. As, it has been previously shown that uptake of apoptotic cells 
alone are insufficient to activate and induce maturation of DC and a second danger signal 
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is required (Nestle et al., 2001), the authors hypothesized that it is possible that UV and 
IR-generated tumor vaccines were only able to partially activate DCs and hence resulted 
in a less optimal T-cell immune response. This was supported by their findings that UV-
generated lysates were only able to partially activate DCs as evidenced by the increase in 
MHC class II and CD86 expression but no increase in IL-12 production, and that both 
UV and ionizing radiation-generated vaccines were not as effective as PDT vaccines in 
stimulating tumor specific IFN-γ-secreting cells and increasing splenic cytolytic activity.  
Subsequently, Korbelik and Sun, 2006 conducted a similar study examining the 
effects of PDT-generated tumor vaccine on poorly immunogenic murine squamous cell 
carcinoma (SCCVII). They too discovered that the efficacy of PDT-generated vaccines 
was superior to lysed cell and x-ray-treated cell generated vaccines. They identified two 
elements important for the unique capacity of PDT to generate an effective cancer 
vaccine ie. surface expression of HSP 70 and binding of complement proteins on PDT-
treated cells. 
Thus far, only 2 studies on DC-based photoimmunotherapy have been reported 
and both have shown the benefit of this combined therapy (Saji et al, 2006; Jalili et al., 
2004). Both these studies utilized intra-tumoral injection of DCs harvested ex vivo. Intra-
tumor injection of DCs overcomes the problems associated with ex vivo antigen-loading 
of DCs. In vivo loading of DCs is thought to be superior to ex vivo loading as this exposes 
and primes DCs to the potentially thousands of antigens present in tumors as opposed to 
the 1 or 2 antigens used in ex vivo techniques. However, it is essential to remember that 
their methods were still not entirely in vivo as the expansion of DCs were performed ex 
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vivo which has been shown to be associated with potential limitations and practical 
problems especially cost and manpower.  
 The method utilized in the present study of DC-based immunotherapy which is 
entirely in vivo will theoretically overcome all the potential problems associated with 
both ex vivo DC expansion and in vitro antigen loading and activation of DCs. The 
potential advantages of the entirely in vivo method is not only that DCs are potentially 
primed by numerous tumor antigens but that DCs of different lineages are expanded 
which may be required to produce an optimal T-cell response. However, it is important to 
highlight important potential limitations associated with the in vivo expansion of DCs. It 
has been reported that DCs in patients with malignancy are functionally impaired DCs 
and theoretically, DC expansion may result in increased in numbers of DCs which are not 
useful. Furthermore, it has also been demonstrated that an increase in the numbers of 
immature DC may result in immune tolerance rather than immune stimulation (Lutz and 
Schuler, 2002).   
            The results in the present study demonstrate that photoimmunotherapy utilizing 
the in vivo expansion of DC has a similar systemic anti-tumor immunity effect as that of 
the in vitro expansion and intratumoral injection of DCs method utilized by Jalili et al 
and Saji et al (Jalili et al., 2004; Saji et al., 2006). Photoimmunotherapy not only retarded 
contralateral tumor growth when exposed to a second tumor challenge but it also 
suppressed the growth of an established contralateral tumor. These findings suggest that 
PDT destruction of melanoma results in an optimal milleu for the priming and maturation 
of DCs resulting in an effective tumor specific immune response. These findings also 
suggest that photoimmunotherapy may play an important role in the clinical setting in the 
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delay or prevention of the development of metastases as well as for the palliation of 
advanced metastatic disease. The effectiveness of photoimmunotherapy demonstrated in 
this study on B16 melanoma cells which is considered poorly immunogenic (Saji et al., 
2006) also suggests that it need not be restricted to only highly immunogenic tumors. 
            The pathophysiology of combination therapy with PDT and DC expansion has 
been previously described (Saji et al., 2006; Jalili et al., 2004). PDT induces cell death 
via both necrosis and apoptosis following oxidative stress. It also induces an intense local 
inflammatory reaction via the rapid release of proinflammatory mediators released from 
tumor cells and endothelial cells (Agarwal, et al., 1993). Cytokines that are involved in 
the recruitment of neutrophils and myeloid cells such as TNF, IL-1β and IL-6 are also 
secreted by PDT-treated cells (Jalili et al., 2004). These complex reactions induce an anti-
tumor immune response and are able to activate DCs. The induction of HSPs by PDT-
treated cells have been proposed as a key step in the activation of DCs (Jalili et al., 2004). 
HSPs have been identified as key activators of DCs giving rise to potent 
immunoregulatory activities (Feng, et al., 2001; Flohe et al., 2003) and several studies 
have demonstrated that HSPs are expressed after PDT (Gomer et al., 1996; Wang et al., 
2002). Finally, cytotoxic T cells have been shown to be responsible for the regression of 
the tumor and CD8+ T cells have been further identified as the major effector cells. 
             
4.4 Effectiveness of photoimmunotherapy on primary tumor. 
The present study demonstrated that both PDT and photoimmunotherapy were 
effective in retarding primary tumor growth as compared to control. However, the effect 
of photoimmunotherapy was not superior to PDT alone in the treatment of primary B16 
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tumors when a therapeutic dose of PDT was used. This is in contrast to the findings of 
both Jalili et al and Saji et al that photoimmunotherapy with intra-tumoral injection of 
DCs was superior to PDT alone in controlling primary tumor growth of CT26 colorectal 
carcinoma cells and both CT26 colorectal carcinoma and B16 melanoma cells 
respectively (Jalili et al, 2004., Saji et al., 2006). It may be possible to demonstrate the 
superiority of photoimmunotherapy over PDT if a sub-therapeutic dose of PDT with 
minimal tumor destruction is administered as in the study by Saji et al., 2006. Hence, 
although Saji et al., 2006 demonstrated the superiority of photoimmunotherapy over PDT 
alone in the treatment of primary B16 tumors, it is likely that this is probably true only 
when a sub-therapeutic dose of PDT is administered.  In the clinical setting, the benefit of 
photoimmunotherapy over PDT alone for the treatment of primary tumors will likely be 
limited to situations whereby one is unable to administer a therapeutic dose of PDT to the 
entire tumor due to toxicity. 
 
4.5 Effectiveness of photoimmunotherapy in generating an tumor specific anti-
tumor vaccine 
The findings in this study were consistent with that of Saji et al., 2006 that 
photoimmunotherapy treated mice demonstrated anti-tumor immunity and were more 
resistant to a second tumor challenge. The findings also demonstrated that the anti-tumor 
immunity was specific as photoimmunotherapy of B16 cells had no effect on a second 
tumor challenge with RMA (Figure 17). This finding provides evidence that the anti-
tumor response induced by photoimmunotherapy is tumor-specific and hence is most 
likely mediated by the tumor-specific acquired immune response. This finding is 
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consistent with the findings from previous studies on photoimmunotherapy and PDT-
generated vaccines that the acquired immune response which is tumor specific plays a 
key role in anti-tumor activity after PDT (Korbelik and Sun, 2006). Clinically, these 
effects may be useful in preventing the development of metachronous tumors especially 
in malignancies associated with field change such as head and neck cancers and 
hepatocellular carcinoma whereby the development of second primary cancers are not 
uncommon. However, further experiments need to be performed to determine if the 
tumor-specific immune effects of photoimmunotherapy are durable. 
 
4.6 Effect of photoimmunotherapy on a pre-established contralateral tumor 
(metastatic model) 
In this study, photoimmunotherapy was effective and superior to PDT and control in 
retarding the growth of the contralateral tumor. This too was consistent with the findings 
of Jalili et al., 2004 and Saji et al., 2006. However, photoimmunotherapy was ineffective 
when the established contralateral tumor was large (Figure 16) suggesting that when 
tumors were large, the immune system was overwhelmed and photoimmunotherapy was 
ineffective.  This finding has important implications in the clinical setting suggesting that 
photoimmunotherapy should be administered early when distant metastases are small and 
an efficient anti-tumor response can be mounted.  
 
4.7 Adoptive transfer 
The development of effective adoptive transfer of T-cells as a strategy for 
immunotherapy in human malignancies has met with many obstacles (Riddel, 2007). One 
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of the major limitations of adoptive therapy is to be able to isolate antigen-specific T 
lymphocytes consistently and successfully (Stauss et al., 2007). Efficient methods for 
selective isolation of high avidity T cells are still in the process of being developed. 
Moreover, it is not easy to isolate T cells with high avidity for tumor-associated antigens 
because of acquisition of tolerance to tumor antigens (Drake et al., 2006). Low avidity 
cytotoxic T-lymphocytes have been shown to be less effective in tumor protection in vivo 
(Zeh et al., 1999). There is also the problem of ensuring that transferred T cells are still 
tumor-reactive in the in vivo state following adoptive transfer (Blattman and Greenberg, 
2004; Gattinoni et al., 2006). Failure of clinical response to adoptive transfer of 
laboratory expanded T cells have been attributed to evasion of tumor-specific immune 
responses by immunosuppressive factors (Lizee et al., 2007). Another possible reason for 
the failure of adoptive transfer in this study is the timing at which the spleen of 
photoimmunotherapy treated mice were harvest. In this study, splenocytes were harvested 
5 to 7 days after treatment as opposed to the study by Saji et al. (2006) whereby the 
splenocytes were harvested 4 weeks after treatment. It is possible that the shorter time 
period in this study was insufficient for the development of adequate numbers of tumor-
specific memory T-cells in the spleen for effective adoptive transfer. It was not possible 
to wait 4 weeks for the harvesting of splenocytes in this study as before this time period 
the tumors had already reached the size threshold whereby the mice were required to be 
euthanized.  
         The lack of efficacy seen in adoptive transfer in this study may be due to the above  
reasons. The efficacy of PDT-generated vaccine has also been shown to be dependent on 
the number of cells used for vaccination. In a recent study by Korbelik and Sun, the 
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efficacy of PDT-generated vaccine was compared using various concentrations of 5, 10, 
20 and 50 million cells. It was shown that a vaccine using 20 million cells produced the 
greatest tumor retardation (Korbelik and Sun, 2006). It is possible that the number of 
lymphocytes used in this study was insufficient. Furthermore the presence of regulatory 
cells that has the potential to inhibit T-cell responses cannot be excluded (Ward and  
Kaufman, 2007). In addition there is also the possibility of hitherto unknown tumor 
escape mechanisms. Interestingly, a very recent finding by Matter et al. (2007) showed 
that contrary to expectation, adoptive T-cell therapy could reduce tumor surveillance and 
enhance tumor growth rather than regression.  
  
4.8 Conclusion 
The main findings in this study are listed below: 
1. HY-PDT can induce tumor destruction in melanoma in mice without toxic effects  
2. Higher light doses are required for effective tumor destruction  
3. The mode of cell death of B16 melanoma after HY-PDT after both 1 hour and 6 hours 
incubation was mainly via necrosis. Apoptosis occurred at a much lesser extent. 
4. Both photoimmunotherapy and PDT retarded the growth of primary B16 melanoma 
cells. 
5. The anti-tumor effect of photoimmunotherapy against the primary tumor was not 
superior to PDT. 
6. Photoimmunotherapy was effective in generating an anti-tumor vaccine. Tumors 
treated with photoimmunotherapy were resistant against a second tumor challenge. 
7. The anti-tumor immunity generated by photoimmunotherapy was tumor-specific. 
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8. Photoimmunotherapy was effective in conferring systemic anti-tumor effects against 
small distant untreated tumors. 
9. The systemic anti-tumor effect of photoimmunotherapy was ineffective when distant 
untreated tumors were large in size. 
10. Adoptive transfer of splenocytes of photoimmunotherapy-treated mice failed to 
produce an effective anti-tumor response.   
 
In conclusion, the data in our present study demonstrates that high doses of HY-
PDT is effective against melanoma and is the first study to demonstrate the anti-tumor 
effects of HY-PDT on melanoma. It also demonstrates that photoimmunotherapy using 
HY-PDT and in vivo DC expansion by pNGVL3-Flex plasmid DNA results in an 
effective systemic anti-tumor immune response which is tumor-specific and suppresses 
tumor growth at distant sites. This is the first study to demonstrate the effective use of 
photoimmunotherapy via in vivo DC expansion. These results suggest that the addition of 
DC-based immune therapy to PDT results in systemic effects which may be useful in the 
clinical setting for delaying and preventing the development of a second primary and for 










































4.9 Further studies 
Preclinical studies 
Further studies should be performed to determine the effect of different light and 
drug dose of HY-PDT on mode of cell death ie. apoptosis and necrosis. Once this is 
determined, it would be interesting to investigate how the relative proportions of 
apoptosis and necrosis affect the immune response triggered and more importantly the 
outcome of photoimmunotherapy. Studies should be also conducted to determine the 
pathophysiology of HY-mediated tumor destruction in melanoma. It is intriguing how  
HY-PDT despite its short wavelength is able to mediate the destruction of melanoma.  
Further experiments should be performed to obtain further insight and to compare 
the host response and pathophysiology of PDT and photoimmunotherapy induced tumor-
destruction. Flow cytometry of can be used to examine the cells of regional lymph nodes 
(tumor-draining lymph nodes) to determine the percentage increase of T-lymphocyte, B-
lymphocyte and DC population.  Furthermore, the proportion of various subtypes of T-
cells especially cells bearing the CD44+ CD45RB- memory phenotype should be 
determined (Korbelik and Sun, 2006). Flow cytometry should also be used to analyze the 
cells retrieved from the tumor site comparing cells from tumors in the control, PDT and 
photoimmunotherapy treated mice. Specifically, in addition to proportion of DCs and 
lymphocytes, the cells should be studied to determine if complement proteins and HSPs 
are expressed as these have been fingered as possible key players for effective 
photoimmunotherapy. The role of neutrophils in photoimmunotherapy should also be 
studied as it has been recently shown that they play a key role in PDT-induced systemic 
anti-tumor immunity (Kousis et al., 2007). Experiments should be performed to 
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determine the efficacy of photoimmunotherapy using light doses which stimulate 
different levels of neutrophil infiltration (Henderson et al., 2004) to determine the role of 
neutrophils on DC-based photoimmunotherapy. ELISPOT assays can also be used for the 
in vitro characterization of the antitumor immune response induced by PDT and 
photoimmunotherapy (Saji et al., 2006). These essays can be used to determine if 
splenocytes of photoimmunotherapy treated mice contained significantly more tumor-
specific IFN-λ-secreting cells than splenocytes from the other treatment groups.   
Cytotoxic activity of lymph node cells and splenocytes after PDT and 
photoimmunotherapy should be tested in a standard (51Cr) release assay, as described 
previously (Golab et al., 2003). After photoimmunotherapy and PDT, the cytotoxic 
assays are used to measure spontaneous activity (NK cells) and specific cytotoxicity 
(CD8+ T cells) (Jalil et al., 2004). Confocal laser microscopy studies can be performed to 
determine the increased expression of various HSPs.  
 
Clinical studies 
Considering the large numbers of patients whom have been treated via PDT over 
the past 30 years (Castano et al., 2006), there have been few studies examining the effects 
of PDT on the human immune system much less the effects of photoimmunotherapy. 
Presently, only a few case reports examining the effects of PDT on the immune system 
and the effects of photoimmunotherapy in humans have been reported in the literature 
(Abel-Hady et al., 2001; Shikowitz et al., 2005; Thong et al., 2007). Systematic studies 
examining the effects of PDT and photoimmunotherapy on cancers and the resultant 
immune responses in humans are long overdue. Phase I and II clinical trials should also 
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be performed to study the effects of in vivo DC-based photoimmunotherapy in human 
cancers  especially melanoma as there is presently no effective treatment for this.  
Currently, although the use of PDT in combination with immune therapy ie. 
photoimmunotherapy is still in its infancy, its future looks bright as this modality seems 
to be based on extremely sound scientific principles. However, it is difficult to determine 
if PDT-induced anti-tumor immunity and photoimmunotherapy would someday become 
a standard treatment modality for human cancers in the future or that reports of its use 
would be relegated from scientific journals to history books. Only time will provide us 
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